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The  number  of  genes  known  to cause  human  monogenic  diseases  is increasing  rapidly.  For the  extremely
large,  genetically  and phenotypically  heterogeneous  group  of  intellectual  disability  (ID)  disorders,  more
than  600 causative  genes  have  been  identiﬁed  to date. However,  knowledge  about  the molecular  mech-
anisms  and  networks  disrupted  by  these  genetic  aberrations  is lagging  behind.  The  fruit  ﬂy Drosophila
has  emerged  as a powerful  model  organism  to  close  this  knowledge  gap.  This  review  summarizes  recent
achievements  that  have  been  made  in  this  model  and  envisions  its  future  contribution  to our under-
standing  of  ID genetics  and  neuropathology.  The  available  resources  and efﬁciency  of Drosophila  place
it in  a  position  to  tackle  the  main  challenges  in  the  ﬁeld:  mapping  functional  modules  of  ID genes  to
provide  conceptually  novel  insights  into  the  genetic  control  of  cognition,  tailored  functional  studies  to
improve  ‘next-generation’  diagnostics,  and  identiﬁcation  of  reversible  ID phenotypes  and  medication.
Drosophila’s  behavioral  repertoire  and  powerful  genetics  also  open  up  perspectives  for modeling  genet-
ically  complex  forms  of  ID  and  neuropsychiatric  disorders,  which  overlap  in their genetic  etiologies.  In
conclusion,  Drosophila  provides  many  opportunities  to advance  future  medical  genomics  of  early  onset
cognitive  disorders.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
The human brain is one of nature’s most sophisticated struc-
tures. During brain development, billions of neurons are born and
organized into complex networks. Post development, the brain
maintains structural and functional plasticity, which allows us to
learn, memorize and to adapt our behavior accordingly. Genetic
defects that compromise brain development, function, and plas-
ticity can cause cognitive disorders such as intellectual disability
(ID).
ID, previously referred to as mental retardation, is a collective
term for a group of phenotypically and genetically heterogeneous
diseases that share impaired cognitive function as a common hall-
mark (van Bokhoven, 2011). ID is deﬁned by an IQ lower than
70, presenting with deﬁcits in adaptive behavior (e.g. self-care,
social and interpersonal skills) at an age of onset before 18 years
(American Psychiatric Association, 1994). This deﬁnition distin-
guishes ID from late-onset neurodegenerative disorders. ID affects
as much as 2% of the population and, because of the high frequency
and the need for lifelong care, the total health care expenditures far
exceed those of other mental handicaps (Ropers and Hamel, 2005).
ID is thus a major unsolved medical and socioeconomic challenge
for society (Ropers, 2008).
ID is often distinguished into non-syndromic and syndromic
forms. In syndromic ID, patients present with clinical features in
addition to ID, such as behavioral abnormalities, dysmorphisms,
and metabolic defects. ID can also be classiﬁed by severity, ranging
from mild (IQ 50–69) and moderate ID (IQ 35–49) to severe (IQ
20–34) and profound ID (IQ <20) (American Psychiatric Association,
1994). Clinical and genetic aspects of ID have been extensively
reviewed elsewhere (Ellison et al., 2013; Mefford et al., 2012;
Ropers, 2008; van Bokhoven, 2011). To date, more than 600 genes
have been identiﬁed that cause ID when mutated (our unpublished
literature survey), yet the majority of ID genes still await discovery
(van Bokhoven, 2011).
Because of the genetic heterogeneity, it has been a major chal-
lenge to comprehensively investigate genetic causes of ID. The
fruit ﬂy Drosophila emerges as a very powerful organism for such
endeavors. In this review, we aim to provide an overview on the
contribution that Drosophila research has made to our understand-
ing of ID, and thus to the genetic control of cognition. We further
discuss future challenges and current limitations in ID-related
research, including identiﬁcation of molecular pathways that are
disrupted in ID, bottlenecks in diagnostics, and development of
therapeutic intervention. We specify how Drosophila can help to
provide conceptually novel insights into these matters. Finally, we
debate how the lessons learnt from ID research in Drosophila can
be applied to other cognitive disorders with complex and poorly
understood genetics.
2. Advantages and applications of Drosophila as a model for
cognitive disorders
Understanding the function of the human brain is one of the
main challenges in neuroscience. Researchers have turned toward
organisms with more simple and easily manipulable brains to study
fundamental brain processes on a molecular, cellular and circuit
level. The Drosophila brain is, with approximately 100,000 neurons,
relatively small yet sufﬁciently complex to provide a suitable model
(Bellen et al., 2010). Despite the evolutionary distance between ﬂies
and humans, a strong conservation of genes, pathways and regu-
latory molecular networks has been demonstrated. 75% of human
disease genes have related sequences in Drosophila (Bier, 2005).
Correspondingly, we  found unambiguous counterparts for 73% of
ID genes in Drosophila (Oortveld et al., 2013).
In contrast to mammalian models, the generation of ﬂy mutants
is easy, cheap and fast. Moreover, the pool of publically available
stocks that can be readily utilized to induce gain- and loss-of-
function is enormous and steadily increasing (Bellen et al., 2010;
Dietzl et al., 2007; Matthews et al., 2005). Drosophila is well suited
for ID research, as it provides numerous approaches to investi-
gate defects in neuronal morphology and function along with the
possibility to assay cognitive processes. Below and in Fig. 1, we sum-
marize how Drosophila can be used as a model to better understand
the mechanisms underlying ID and other genetic disorders.
1. Gene function can be analyzed at a relatively high throughput
by gene manipulation, followed by characterization of the result-
ing molecular, cellular and/or behavioral phenotypes. Drosophila
mutant, knockdown, or overexpression strains can be ordered
from public stock centers, or new strains can be generated.
2. The primary origin of a phenotype can be determined by cell
type-speciﬁc gene manipulation, e.g. through the use of the UAS-
GAL4 system (Brand and Perrimon, 1993; Duffy, 2002). Large
collections of promoter elements and tools are available that can
be used to individually manipulate speciﬁc tissues, subsets of cell
populations, and even single cells.
3. Temporal requirements for gene function can be determined
through manipulation with molecular switches that can ﬂexibly
be turned on or off. Such temporal information can be of crucial
importance for the prospects of therapeutic intervention.
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Fundamental knowledge
• gene function
• gene identification
• genetic modifiers
• molecular networks
Translational benefits
• new diagnostic approaches
• insights into disease pathology
• understanding clinical variability
• prospects for therapy
Identify genetic modifiers
genetic interaction
Dissection of molecular pathways
genetic interaction & epistasis studies
Test or screen drugs
for ability to rescue phenotype
Determine primary origin of pathology
cell type / tissue-specific manipulation
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inducible manipulation
Test hypotheses
in vivo
Gene function
manipulate gene and find phenotype
Deliver “disease tissue”
for analysis
Fig. 1. Advantages and application of Drosophila as a disease model. The numerous approaches to investigate defects in neuronal morphology and function make Drosophila
well  suited to increase fundamental knowledge and provide translational beneﬁts for ID.
4. Hypotheses can be tested in context of an intact organism. Such
hypotheses can include everything from the presumptive regu-
lation of one gene by another (e.g. using a molecular readout) to
the regulation of a speciﬁc behavior by a certain type of neuron
or neuronal circuit.
5. Disease-relevant tissues can be acquired for analyses in unlim-
ited quantities. In brain research this is an important added
value, since the human brain can only be studied post-mortem
or with non-invasive imaging technology. The Drosophila brain
or neuronal subtypes can be studied by various molecular and
imaging techniques, down to subcellular resolution.
6. Genetic modiﬁer screens can be used to isolate genes that genet-
ically interact with the disease gene of interest. Such modiﬁers
of ﬂy disease model phenotypes represent candidate genes or
risk factors for the same or related disease.
7. The possibility to genetically combine two or more mutations
in different genes has made it possible to dissect molecular
networks, for example the hierarchy of signaling pathways.
8. Finally, it is an excellent tool for testing large numbers of chem-
ical compounds for their ability to alleviate ﬂy phenotypes,
paving the way for therapeutic trials in mammalian models and
humans.
The fundamental knowledge that can be generated in this man-
ner has great potential to ﬁnd its way into the clinic (Fig. 1). Taken
together, these features make Drosophila an extremely valuable
organism to investigate human disease of the brain including ID.
3. Drosophila models of ID
At the beginning of the new millennium, Drosophila was used
for the ﬁrst time to address ID gene function. Wan  et al. studied
Fmr1, the Drosophila ortholog of the Fragile X mental retardation
gene (Wan  et al., 2000). Drosophila has now been used for over a
decade to model ID, which has provided a large amount of disease-
relevant information. In this chapter, we summarize some of these
insights into ID gene function and pathology.
3.1. The contribution of behavioral tests to study ID
One of the advantages of working with an animal model such
as Drosophila is that the effect of gene manipulation can be studied
at the level of the whole organism. ID genes have been tested for
behavioral defects, starting from relatively simple and proceeding
to more complex behaviors. The role of some ID genes has been fur-
ther dissected and mapped to speciﬁc tissues or neuronal circuits.
A range of assays has been used to address simple ﬂy behavior,
including tracking of larval crawling and motor development, neg-
ative geotaxis, phototaxis, and ﬂight assays. These assays are robust,
relatively simple and quick to perform. Mutant ﬂies can be tested
for an effect on their general ﬁtness and, when combined with
cell-speciﬁc manipulation tools, for the requirement of a gene in
a tissue/cell-type of interest. For example, in a ﬂight assay Fmr1
mutant ﬂies display uncoordinated behavior, which has been com-
pared to delayed motor development that is seen in some patients
with Fragile X syndrome (Zhang et al., 2001). The Drosophila model
of Angelman syndrome, a Ube3a mutant strain, has poor climbing
ability indicative of motor dysfunction, resembling severe loss of
motor coordination in patients with Angelman syndrome (Wu  et al.,
2008). However, the degree and pattern of neuronal dysfunction
can differ between humans and Drosophila. For example, inacti-
vating mutations in Drosophila Nab2, the ortholog of the human
gene ZC3H14, cause defects in locomotion, whereas the patients are
reported to have a non-syndromic ID phenotype (Pak et al., 2011).
Drosophila also offers plenty of opportunities to test more
complex and cognitive behaviors, most importantly learning and
memory. Since ID patients suffer from several aspects of impaired
learning and memory capabilities (Bolduc and Tully, 2009), it is of
great interest to investigate the role of ID gene orthologs in these
processes. Indeed, the number of such studies has been increasing
rapidly within the past years. The most commonly used paradigms
were olfactory learning and courtship conditioning (Bolduc and
Tully, 2009), but also spatial learning and habituation paradigms
have been applied to ID models (see below). Learning and/or
memory defects have been found associated with mutations in
Drosophila orthologs of GNAS (Connolly et al., 1996), NF1 (Guo et al.,
2000), FLNA (Dubnau et al., 2003), RSK2 (Putz et al., 2004), FMR1
(McBride et al., 2005), PRSS12 (Didelot et al., 2006), UBE3A (Wu
et al., 2008), PQBP1 (Tamura et al., 2010), EHMT1 (Kramer et al.,
2011), NSUN2 (Abbasi-Moheb et al., 2012), ANK3 (Iqbal et al., 2013),
CEP89 (van Bon et al., 2013) and GATAD2B (Willemsen et al., 2013).
Most studies so far have only utilized a single paradigm to inves-
tigate learning and/or memory in a speciﬁc ID model, whereby the
choice of the assay was not based on the clinical phenotype or
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biology of the gene but rather determined by the expertise of the
investigating laboratory. It is interesting to note that some multi-
paradigm studies found distinct mutant phenotypes, depending on
the type of mutation and behavioral paradigm tested. For exam-
ple, Drosophila S6kII mutants were tested in two  learning tasks:
operant place learning and Pavlovian olfactory conditioning (Putz
et al., 2004). The S6kII protein is part of the Ras extracellular signal-
regulated kinase (ERK) signaling pathway and the human ortholog
RPS6KA3 is associated with Cofﬁn-Lowry syndrome. In three tested
S6kII mutants, expression was reduced through a P-element inser-
tion, a partial, or a full gene deletion. The P-element insertion
mutant only affected operant place learning. The partial deletion
mutant, lacking part of the N-terminal kinase domain, performed
poorly in both learning tasks. The null mutant surprisingly only
affected olfactory learning. These ﬁndings suggest that the type
of allele can determine the behavioral read-out, even when all
alleles presumably represent (partial) loss-of-function conditions.
This appears analogous to the human situation where extensive
clinical variability is associated with allelic mutations. Work on
EHMT mutant ﬂies, the Drosophila model of Kleefstra syndrome,
illustrates that the function of a gene also depends on the behav-
ioral context. EHMT mutants show defects in habituation, a form
of non-associative learning, whereas learning in the courtship con-
ditioning paradigm is unaffected (Kramer et al., 2011). Differences
between paradigms have also been found in classic learning and
memory mutants (for a review see e.g. (Engel and Wu,  2009)) and
may  depend on expression patterns of the gene, architecture of
the behavior-underlying circuit or different neuronal properties.
This makes it difﬁcult to impossible, with current knowledge, to
rationalize which paradigm to preferably use when modeling ID.
The combination of cognitive tests and genetic approaches in
Drosophila can be used to distinguish between genes that execute
a speciﬁc neuronal function in cognitive processes and genes that
act elsewhere, causing ID in an indirect manner. This is of partic-
ular interest when ID patients present with a broader spectrum of
clinical features, like Kleefstra syndrome where ID patients present
with developmental delay, hypotonia, distinct facial and other fea-
tures (Willemsen et al., 2012). Transgenic re-expression of EHMT in
all neurons (‘pan-neuronally’) rescued courtship memory defects in
EHMT mutant ﬂies, indicating a direct role of EHMT in cognitive pro-
cesses (Kramer et al., 2011). Very similarly, the autosomal-recessive
ID gene Nsun2,  associated with microcephaly and additional clin-
ical features, was shown to be essential for short-term memory
in the aversive olfactory conditioning paradigm. The phenotype
was rescued by pan-neuronal re-expression of Nsun2 in the mutant
background (Abbasi-Moheb et al., 2012).
The same and other conditional strategies, often exploiting the
UAS-GAL4 system, can be applied to identify the subset of neu-
rons that are important for speciﬁc behaviors (Fig. 1). A brain
structure called the mushroom body is known to be required
for several forms of learning and memory in Drosophila. Re-
expression of EHMT in mushroom body neurons was  sufﬁcient
to rescue courtship memory defects shown by EHMT mutants
(Kramer et al., 2011). Mutant ﬂies of the neurotrypsin-related
gene Tequila display defective long-term memory in the olfac-
tory learning paradigm (Didelot et al., 2006). RNAi-mediated
knockdown of Tequila in mushroom body neurons was  suf-
ﬁcient to cause the defects. Likewise, Wah, the ortholog of
KANSL1, and simj, the ortholog of GATAD2B, were investigated.
Mushroom body-speciﬁc knockdown of wah reduces learning abil-
ity in courtship conditioning and pan-neuronal knockdown of
simj decreases light-off jump reﬂex habituation (non-associative
learning) (Koolen et al., 2012; Willemsen et al., 2013). In addi-
tion, 10 out of 37 Drosophila orthologs of recently identiﬁed ID
candidate genes (Najmabadi et al., 2011) are necessary for nor-
mal  long-term memory in courtship conditioning, as found by
pan-neuronal RNAi experiments (K. Keleman, personal communi-
cation).
In summary, learning and memory function is affected in a sig-
niﬁcant number of ID models. Such ﬁndings and models provide
additional evidence for the role of the investigated genes in cog-
nitive processes, and allow for further dissection of the underlying
molecular and cellular defects.
3.2. Neuronal development and architecture
Drosophila offers many opportunities to study the role of genes
in the organization of the brain and its nervous system in greater
detail. Here we  provide an overview on how structural information
on synapses, dendrites and axons helps to further understand the
cellular basis of ID.
A signiﬁcant number of ID genes encode proteins involved in
synapse biology (van Bokhoven, 2011). Because of this observation
and since synaptic morphology and function is important for cogni-
tive processes, many studies put emphasis on determining the role
of ID genes at a Drosophila synapse. The Drosophila neuromuscular
junction (NMJ) has been widely used to address questions related to
mechanisms underlying neurotransmitter release, synapse forma-
tion and physiology (Ruiz-Canada and Budnik, 2006a). Like many
central excitatory mammalian synapses, the Drosophila NMJ  is
glutamatergic, contains similar molecular components and is reg-
ulated by orthologous pathways. The synaptic terminals of the
NMJ  are organized in boutons and each bouton contains numer-
ous presynaptic release sites, known as active zones. Zhang et al.
showed that loss of FMR1 causes synaptic overgrowth, whereas
overexpression causes undergrowth, with fewer (but larger) synap-
tic boutons (Zhang et al., 2001). Based on phenotypic similarities, a
functional link between Fmr1 and futsch, a microtubule-associated
protein, was  hypothesized and conﬁrmed by a double mutant con-
dition that reversed the Fmr1 mutant overgrowth phenotype. The
importance of the microtubule network in NMJ  development and
function was further underscored by a study that investigated the
tubulin-speciﬁc chaperone E gene (TBCE), which is linked to the
congenital hypoparathyroidism-retardation-dysmorphism (HRD)
syndrome (Jin et al., 2009). Drosophila tbce was found to func-
tion both pre- and postsynaptically. Knockdown at either side
of the NMJ  caused an increase in the number of branches and
boutons, whereas the bouton area was smaller. This observation
corresponds with the hypothesis that synaptic growth depends on
microtubule dynamics, but not necessarily on the absolute quantity
of microtubules (Ruiz-Canada and Budnik, 2006b). In addition to
microtubule-related ID genes, NMJ  structural abnormalities have
recently been described in ID ﬂy models of mitochondria-related
proteins, such as Cep89 and its Drosophila ortholog CG8214 (van
Bon et al., 2013), UbcD6 and its Drosophila ortholog Rad6a (Haddad
et al., 2013), adhesion molecules like the Neurexins (Zweier et al.,
2009), intracellular phospholipases (Schuurs-Hoeijmakers et al.,
2012) and proteins involved in chromatin remodeling, like KANSL1
and GATAD2B and their Drosophila orthologs wah  (Koolen et al.,
2012) and simj (Willemsen et al., 2013), respectively.
Beyond morphological analyses, the NMJ  is a suitable model
to directly measure the effect of mutations on neurotransmis-
sion. Larval muscles and motor nerves are relatively large; this
genetically traceable synapse is therefore fully amenable to elec-
trophysiological analyses. For example, the combination of pre-
versus postsynaptic manipulation and electrophysiology revealed
that tbce is exclusively required presynaptically for normal neu-
rotransmission. Altered levels of presynaptic tbce results in an
increase in the excitatory junction potential (EJP) and miniature
EJP (mEJP) amplitudes, whereas postsynaptic manipulation does
not change these parameters (Jin et al., 2009). In a large-scale
screen focused on postsynaptic glutamate receptor localization,
330 M. van der Voet et al. / Neuroscience and Biobehavioral Reviews 46 (2014) 326–342
mutations in rt, the Drosophila ortholog of POMT1,  were found to
cause a reduced level of GluRIIB (Wairkar et al., 2008). Mutations
in POMT1 are linked to muscular dystrophy-dystroglycanopathies
with ID (van Reeuwijk et al., 2006). Drosophila rt synapses show
decreased synaptic strength and release probability but no struc-
tural NMJ  defects. These defects were only rescued when rt was
simultaneously re-expressed pre- and postsynaptically (Wairkar
et al., 2008). Moreover, it was demonstrated that rt is required to
glycosylate the Drosophila dystroglycan ortholog Dg in vivo, which
likely is essential for proper synapse function.
The giant ﬁber system (GFS) has been used to study mor-
phology and function of central synapses. The GFS mediates the
escape response of adult ﬂies and connects with the dorsal longi-
tudinal motoneurons and the Tergo Trochanteral Muscle neuron
(TTMn). This system was used to study the role of Drosophila
Nrg, whose ortholog L1CAM is associated to a variety of neu-
rological diseases, in central synapse formation (Godenschwege
et al., 2006). Whereas Nrg null mutants displayed severe axon
guidance defects that precluded synaptic analyses, ﬂies with
the homozygous missense mutation Nrg849, located at a similar
position as one of the many identiﬁed human pathological muta-
tions, showed such defects only with low penetrance. The Nrg849
mutants were characterized by structurally and functionally com-
promised synaptic connections between GFS and TTMn neurons
(Godenschwege et al., 2006; Hortsch et al., 2009). Expression of
vertebrate L1CAM simultaneously at both the pre- and postsynap-
tic site was able to rescue these synaptic defects (Godenschwege
et al., 2006).
The Drosophila central synapse of the VS1 neuron of the
lobula plate vertical system was recently found to be regu-
lated by the Fragile X protein Fmr1. The VS1 neuron shows
small actin-enriched protrusions that are morphologically and
functionally similar to dendritic spines, mammalian postsynap-
tic compartments, making this synapse an attractive postsynaptic
system to study in ID models. In wild-type ﬂies, VS1 spine
number and length increase after sleep deprivation and show
pruning when ﬂies are allowed to sleep. FMR1 is required for
this sleep-dependent synaptic renormalization. This study pro-
vided compelling structural evidence for sleep regulating synaptic
homeostasis and for involvement of an ID gene therein (Bushey
et al., 2011).
Changes in dendritic arborization are commonly observed in
ID patients (Kaufmann and Moser, 2000) and might contribute to
their cognitive impairment. The dendritic arborization (DA) neu-
rons in Drosophila,  also named multiple dendritic neurons, are a
well-suited model to study dendrite architecture and arborization.
DA neurons, particularly the morphologically complex class IV DA
neurons (Jan and Jan, 2010), have been examined in a handful of
ﬂy models of ID genes. Fmr1 mutants show an elevated number
of higher-order dendritic branches, reintroducing one copy of the
wild-type Fmr1 gene reversed the phenotype. Overexpression of
Fmr1 has the opposite effect, revealing a dosage-dependent mech-
anism (Lee et al., 2003). Loss of Ube3a or EHMT in the Angelman
and Kleefstra syndrome ﬂy models results in reduced dendritic
branching, which suggests that a dendritic pathology might con-
tribute to the human phenotypes (Kramer and van Bokhoven,
2009; Lu et al., 2009). More recently dendrite defects were also
reported in the Ube3a and Ehmt1 mouse models (Balemans et al.,
2013; Miao et al., 2013). The importance of dendrite morphology
in the etiology of ID was also applied to strengthen the hypoth-
esis that haploinsufﬁciency of the CDK19 gene causes ID with
microcephaly and congenital retinal folds in a single patient. Knock-
down of the CDK19 Drosophila ortholog Cdk8 in DA neurons causes
reduced dendritic ﬁelds and reduced dendritic complexity, sup-
porting the link of CDK19 to the ID phenotype (Mukhopadhyay et al.,
2010).
Outgrowing axons follow a precise path during development
to connect to other neurons via their terminal synapses. Connec-
tions must be made with the correct targets, which is challenging
considering the distance and large number of pathﬁnding choices.
It is likely that axonal biology, like other aspects of neuronal
morphology, plays an important role in the etiology of ID. White
matter tracts in the human brain, rich in myelinated axons, can
be visualized using diffusion tensor imaging (Huang and Vasung,
2013). However, due to technical limitations, including lack of a
method analogous to dendritic Golgi staining that would allow
tracing of single axons, this ﬁeld in humans remains largely unex-
plored. Drosophila can be used to study the processes of axon
growth, pathﬁnding and branching by labeling subsets or single
axons. Work on the Drosophila Fragile X model played a pioneer-
ing role linking Fmr1 to these processes. Loss of Fmr1 strongly
affects neurite extension and axon guidance of both dorsal clus-
ter and lateral neurons, but not photoreceptor neurons (Morales
et al., 2002). Ectopic axon branching patterns and axon over-
growth have also been observed in neurons of the mushroom
body (Michel et al., 2004; Pan et al., 2004). In mutant Fmr1 mush-
room body  neurons, these phenotypes have been shown to
result from defects in activity-dependent axon pruning (Tessier and
Broadie, 2008). Evidence for axonal functions of the Fragile X pro-
tein also accumulates in mammalian systems (Section 4.2). It is to
be hoped that further progress in human brain imaging techniques
in combination with functional data coming from model organ-
isms will shed more light on the contribution of axonal biology on
ID.
3.3. ID gene function and circadian rhythm
Apart from defects in the above-discussed aspects of neuronal
development and function that are common to at least some ID
models, work in Drosophila linked ID gene function to circadian
rhythm. Fmr1 mutant ﬂies are arrhythmic, with an erratic pat-
tern of locomotor activity including periods of hyperactivity, and
defects in circadian period upon overexpression (Dockendorff et al.,
2002; Inoue et al., 2002; Morales et al., 2002). Fmr1 was  shown to
be required for normal cAMP response element-binding protein
(CREB) activity, downstream of clock neurons (Dockendorff et al.,
2002). Subsequently, circadian rhythm defects were also found
for the mammalian Fragile X protein family (in Fmr1/Fxr2 double
mutant mice, hetero- and homozygotes) (Zhang et al., 2008). Alter-
ations in the circadian rhythm are also increasingly considered as
a cause rather than a consequence of neuropsychiatric disorders
(Menet and Rosbash, 2011). Given the observed sleep disorders
in Fragile X patients and the overlap of ID with neuropsychiatric
disorders (further discussed in chapter 7) alterations in circadian
rhythms might contribute to behavioral alterations in ID patients
(Zhang et al., 2008). Circadian rhythm defects in other ID models
such as Ube3a mutant ﬂies (Wu  et al., 2008) further support this
idea.
3.4. Defective RNAi machinery and ID
Drosophila work on Fragile X syndrome pioneered the link
between the RNAi machinery and human disease. Two back-to-
back papers published in 2002 discovered an association between
Fmr1 and the RNA-induced silencing complex (RISC), and the RNase
III enzyme Dicer, implicating Fmr1 as part of the RNAi-related appa-
ratus (Caudy et al., 2002; Ishizuka et al., 2002). Similarly, Dicer
and eIF2C2, the mammalian ortholog of Argonaute-1 (AGO1), were
also found to interact with mammalian FMRP (Jin et al., 2004).
The identiﬁcation of biochemical and genetic interactions of the
Fragile X protein with components of the miRNA pathway, the
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latter demonstrated in Drosophila,  could point to a mechanism
through which the protein exerts its function (Jin et al., 2004).
3.5. Contributions of fundamental biological studies
Many studies of Drosophila ID gene orthologs have been per-
formed without the explicit intent to investigate their associated
disease. Examples of ‘incidental ID models’ include studies where
disease gene orthologs were found in unbiased screens to cause
neuronal phenotypes. Such screens have provided unexpected
insights into ID, such as the discovery of a post-mitotic role for
subunits of the cohesin complex, well known for their role in
sister-chromatic cohesion during meiosis and mitosis (Schuldiner
et al., 2008). The cohesin complex subunits NIPBL, SMC1A,  SMC3
and RAD21 are mutated in Cornelia de Lange syndrome (CdLS).
Drosophila studies revealed a function in axon pruning in the mush-
room body and dendrite targeting in olfactory projection neurons.
This post-mitotic role of cohesin was found to be mediated through
altered gene expression (Pauli et al., 2008; Schuldiner et al., 2008).
In addition, a mosaic screen in the Drosophila wing epithelium has
uncovered a role for SMC3 in planar cell polarity (PCP) an important
process in development and function of the nervous system (Mouri
et al., 2012; Tissir and Gofﬁnet, 2013).
Incidental ID models also arise when genes have been inves-
tigated in Drosophila prior to disease implication. The Drosophila
minibrain (mnb) kinase was reported in 1984 to have a critical
role in Drosophila brain development. mnb  mutants have a reduced
brain volume of 40–50% compared to controls, with a drastic reduc-
tion in cell numbers (Fischbach and Heisenberg, 1984). It was
not until 24 years later that de novo truncations in the human
mnb ortholog DYRK1A were identiﬁed in unrelated patients with
a clinical phenotype including a signiﬁcantly reduced brain size
(microcephaly) (Møller et al., 2008). Another example is the class
I helix-loop-helix transcription factor daughterless (da) that con-
trols expression of important neuronal genes and is required for
neural differentiation in Drosophila.  The association to disease came
to light 19 years later when mutations in the human ortholog TCF4
were found to cause Pitt-Hopkins syndrome (PTHS), a severe ID
disorder (Amiel et al., 2007; Brockschmidt et al., 2007; Caudy et al.,
1988; Zweier et al., 2009). Drosophila Ankyrin-2,  the ﬂy ortholog of
human ANK2 and ANK3, was found to be required for synapse sta-
bility in genetic screens. Mutants show synaptic disassembly and
retraction and disrupted neuronal excitability (Koch et al., 2008;
Pielage et al., 2008). Recently, mutations in ANK3 were identiﬁed
in patients with ID and the cognitive defects in humans were sup-
ported by memory defects in Drosophila (Iqbal et al., 2013). These
ﬁndings highlight the importance and direct relevance of funda-
mental studies in Drosophila to human disease.
3.6. Concluding remarks
The Fragile X mental retardation gene was the ﬁrst ID gene to be
studied in Drosophila,  and to date still is the most frequently studied
(Fig. 2). Phenotypes that have been found in the Fragile X ﬂy have
guided research on other Drosophila ID models, such as ﬂy models
of the X-linked Alpha thalassemia/mental retardation syndrome
(ATRX) and genes involved in dystroglycanopathies (Fig. 2) (Fradkin
et al., 2008; Lee et al., 2007; Marrone et al., 2011; Wairkar et al.,
2008; Zhan et al., 2010) and many others as discussed above. This
chapter provided an overview on how Drosophila has been used as
a model to study ID. How Drosophila can be exploited as a model
for ID in future fundamental and translational research is discussed
below.
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Fig. 2. Thirteen years of publications for Drosophila models of intellectual disability.
Thirteen years of Drosophila as a model to study intellectual disability (2000–June
2013) yielded 114 publications, from which more than half (n = 63) describe Fragile
X  syndrome, the most extensively studied ID disorder. Other frequently inves-
tigated syndromes are X-linked alpha-thalassemia/mental retardation syndrome
(n  = 5), Dystroglycanopathies (n = 4) and Rett syndrome (n = 4). The around 30 other
ID  disorders are represented by less than four publications per disorder.
4. Molecular pathways and functional modules in cognitive
(dys)function
4.1. ID genes – different pieces of the same puzzle
Perhaps one of the most important and exciting outcomes of
ID research is the accumulating evidence that ID genes encode
proteins that operate together in common complexes, pathways
or networks. Diverse cellular functions and mechanisms have
emerged, including intracellular signal transduction pathways that
regulate presynaptic pathways, postsynaptic protein complexes,
cytoskeleton dynamics, epigenetic modulation of chromatin struc-
ture, and transcription (van Bokhoven, 2011).
The pathways most prominently affected by proteins implicated
in ID are Rho and Ras small GTPase signaling cascades. Rho GTPases
are key regulators of actin remodeling. The regulation of the actin
cytoskeleton is important for many aspects of neuronal morphol-
ogy and function, including remodeling and plasticity of actin-rich
dendritic spines. Dendritic spine plasticity is known to correlate
with learning and memory, and abnormal dendritic spines are a
common feature of ID (Kaufmann and Moser, 2000; Lamprecht and
LeDoux, 2004). ID genes/proteins operating in Rho GTPase path-
ways belong to the classes of Rho GTPase activating proteins (GAPs:
PHN1, SRGAP3/MEGAP, OCRL1),  Rho guanine nucleotide exchange
factors (GEFs: ARHGEF6, ARHGEF9, and FGD1) and Rho GTPase effec-
tor proteins (PAK3) (Dierssen and Ramakers, 2006; Nadif Kasri and
Van Aelst, 2008; Schenck et al., 2004).
The Ras/MAPK pathway is part of cellular signaling cascades
and has pleiotropic functions at the pre- and postsynaptic site.
Presynaptically Ras/MAPK regulates neurotransmitter release at
the axon terminal and depending on the type of neuron, excitatory
or inhibitory, a similar mutation can have opposite downstream
effects. Postsynaptically the Ras/MAPK pathway functions as a
signal integrator at the dendritic spines, where it regulates tran-
scription and translation events (Thomas and Huganir, 2004). The
transcription regulation through transcription factor CREB is essen-
tial for many forms of learning and memory (Lonze and Ginty,
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2002). Genes that are mutated in ID are the Ras GTPases (HRAS
and KRAS), downstream effectors of Ras (RAF1, BRAF, MEK1,  MEK2,
and RPS6KA3/RSK2) and regulators of the Ras/MAPK pathway (SHP2,
SOS1, NF1,  SPRED1, SHOC). The clinically overlapping disorders are
commonly referred to as Rasopathies (Krab et al., 2008b).
Additional pathways in ID have emerged. Among the more than
20 ID genes that encode chromatin remodeling factors are sev-
eral that physically interact and/or functionally cooperate (van
Bokhoven, 2011). MECP2 for example, the methyl-CpG-binding
protein mutated in Rett syndrome, has been found in complexes
with ATRX/XNP, DNMT3B, CREBBP, RPS6KA1/RSK, and CDKL5
(Kramer and van Bokhoven, 2009).
The examples listed above show that identifying these path-
ways greatly improves our knowledge of involved mechanisms,
contributing to our understanding of the patient phenotype. How-
ever, the so far emerging pathways are among the best-investigated
cellular signaling pathways. It will be more challenging to unravel
the role of less investigated or unknown pathways underlying ID.
This will be further discussed in the next section.
4.2. Drosophila to deﬁne molecular pathways and networks
underlying ID
One of the most successful applications of classic Drosophila
genetics is modiﬁer screens. The aim of modiﬁer screens is to iden-
tify second site mutations that modify a phenotype caused by a gene
of interest. Such unbiased screens can reveal functionally related
genes, and thereby additional components of a pathway. A seminal
example is the above-mentioned Ras/MAPK pathway, which was
described and dissected in the context of Drosophila eye develop-
ment (Karim et al., 1996; Therrien et al., 2000). The same principle
can also be utilized in a targeted manner to test for genetic inter-
actions between potentially connected genes.
Loss of the Fragile X protein causes altered synapse morphol-
ogy in human patients, mice and Drosophila models (Zarnescu
et al., 2005). Research in Drosophila revealed that the Fragile X
protein, via the Rac1 effector protein CYFIP/Sra-1, is linked to
actin-remodeling Rho GTPase pathways (Schenck et al., 2003). It
was shown that CYFIP/Sra-1 acts as a Rac1 effector that antago-
nizes Fmr1 function at the Drosophila NMJ. This study provided the
ﬁrst link between signal-dependent cytoskeleton remodeling and
Fragile X syndrome, raising the interesting possibility that actin
remodeling and local protein synthesis at synapses, two  crucial
processes in synaptic plasticity, are directly co-regulated (Schenck
et al., 2003). Further connections between the Fragile X protein and
core players of actin remodeling pathways have been subsequently
revealed. Expression of Drosophila Rac1 and proﬁlin were found
to be controlled by Fmr1, and further ﬁndings in mammalian sys-
tems placed additional emphasis on defects in actin misregulation
as a major problem in Fragile X syndrome and its neuropathology
(Castets et al., 2005; Chen et al., 2010; Lee et al., 2003; Reeve et al.,
2005)
Another link was recently described between the Fragile X pro-
tein and the Down syndrome cell-adhesion molecule (Dscam).
DSCAM is upregulated in Down syndrome and believed to con-
tribute to the neuronal pathology of Trisomy 21 (Alves-Sampaio
et al., 2010; Rachidi and Lopes, 2007). The protein is involved in
intraneuronal self-recognition, axon guidance and synaptic target
selection (Hattori et al., 2008). Drosophila was used as a model to
study the mechanisms via which Dscam exerts these conserved
functions. Following up on earlier ﬁndings that identiﬁed Dscam
as an RNA target of Fmr1, the authors found that Fmr1 sup-
presses Dscam translation to restrict presynaptic arbor growth in
a dose-dependent manner (Brown et al., 2001; Darnell et al., 2011;
Kim et al., 2013a). This is in agreement with a second study that
reported that increased Dscam protein levels, either by Dscam
overexpression or by reduced Fmr1 levels, results in axonal target-
ing errors in pSc mechanosensory neurons (Cvetkovska et al., 2013).
Moreover, reducing Dscam levels in Fmr1 null ﬂies reduces synaptic
targeting errors and rescues behavioral defects. Excess Dscam pro-
tein may  thus be a common molecular mechanism that underlies
altered neural wiring in both disorders (Cvetkovska et al., 2013).
These studies added to an increasing body of evidence that Fmr1,
in addition to its dendritic and postsynaptic functions, plays impor-
tant roles presynaptically and in axons (Contractor, 2013; Patel
et al., 2013).
Shared ID-associated clinical phenotypes, if sufﬁciently charac-
teristic, can generate important novel hypotheses with respect to
proteins that functionally cooperate. Such hypotheses are testable
in Drosophila.  To date, mutations in three genes have been shown to
cause Pitt-Hopkins syndrome (PTHS) and phenotypically overlap-
ping disorders. These genes encode the transcription factor TCF4,
the presynaptic adhesion protein NRXN1, and the distal neurexin-
family member CNTNAP2 (Zweier et al., 2009, 2007). Whereas
the involvement of NRXN1 suggests that PTHS is a synaptopa-
thy, CNTNAP2 organizes nodal microdomains of myelinated axons
and evidence for a synaptic role of the encoded protein has been
lacking. Using Drosophila as a model, it was shown that overex-
pression of either protein, Neurexin-1 ortholog (Nrx-1) or CNTNAP2
ortholog (Nrx-IV), reorganizes synaptic (NMJ) morphology and
induces increased density of active zones, the synaptic domains of
neurotransmitter release. Moreover, dosage of either protein deter-
mines the level of the presynaptic active zone protein bruchpilot,
indicating a possible common molecular mechanism in Nrx-1 and
Nrx-IV mutant conditions. These ﬁndings and the observation of
anti-Nrx-IV immunoreactivity at the investigated synapse argue
that a shared synaptic mechanism contributes to the similar clin-
ical phenotypes in NRXN1 and CNTNAP2 patients (Zweier et al.,
2009). Novel roles for CNTNAP2, including a function in synapse
organization, have subsequently also been reported in mammalian
neurons (Anderson et al., 2012). Of note, the phenotypic commonal-
ities caused by mutations in NRXN1 and CNTNAP2 extends beyond
PTHS. Milder conditions (heterozygous variants or copy-number
variations) have been implicated in an overlapping multitude of
neuropsychiatric disorders, including Autism Spectrum Disorder
(ASD) and Schizophrenia (Zweier et al., 2009). This also matches
the role of TCF4, which in a recent cross-disorder analysis by the
Psychiatric Genomics Consortium, has also been associated to ASD
and Schizophrenia (Psychiatric Genomics Consortium et al., 2013).
Interestingly, it has been recently shown that TCF4 can transacti-
vate the NRXN1  ˇ and CNTNAP2 promoters, suggesting that these
genes are under direct control of TCF4 (Forrest et al., 2012). The
molecular mechanisms that link the three PTHS genes and the
question in how far defects in neuronal differentiation versus
post-mitotic neuronal function contribute to ID in PTHS patients
warrants further investigation. The latter has important conse-
quences for therapeutic intervention strategies (see also chapter 6).
Drosophila has also been successfully applied to extend the
above-mentioned MECP2 functional network (see section 4.1),
even though MECP2 itself is not conserved in Drosophila.  Genetic
interaction experiments in transgenic ﬂies expressing human
MECP2 reveal that reduced dosage of osa is capable of suppress-
ing dendritic defects caused by altered MECP2 levels (Vonhoff et al.,
2012). Osa is the common Drosophila ancestor of human ARID1A and
ARID1B genes, subunits of the SWI/SNF complex that have recently
been shown to cause Cofﬁn-Siris syndrome (Santen et al., 2012;
Tsurusaki et al., 2012). Mutations in ARID1B have also been reported
as a frequent cause of moderate to severe ID with additional clin-
ical features and have been implicated in ASD (Hoyer et al., 2012;
O’Roak et al., 2012). Among the other identiﬁed modiﬁers of MECP2
is pbl,  a target of Ube3a, involved in Angelman syndrome as dis-
cussed above (Cukier et al., 2008). Rett and Angelman syndromes
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are both devastating neurological disorders that share, in addition
to ID, a number of other clinical features, suggesting a possible
mechanistic overlap. Indeed, reduced Ube3a levels are able to sup-
press a MECP2 gain-of-function eye phenotype, MECP2 and Ube3a
proteins physically interact and regulate the expression of shared
target genes (Kim et al., 2013b). Thus, Drosophila studies have estab-
lished connections between MECP2 and other ID genes.
4.3. Addressing other signatures common to (subsets of) ID
disorders
Identifying molecular mechanisms that are shared by ID disor-
ders could provide highly valuable information in several aspects:
(1) for our fundamental understanding of the biology underly-
ing ID, (2) as biomarkers with potential applications in future
diagnostics, and (3) to deﬁne common targets for future thera-
peutic intervention. Such common mechanisms do not necessarily
need to represent signaling pathways in which ID gene products
directly operate. Shared transcriptional or metabolic dysregulation
and other molecular ‘signatures’ can be important as well, even
if indirectly caused. First reported examples of such signatures
include altered immediate early gene expression through mutated
ID genes MED23, MED12 or ERCC2/XPD (Hashimoto et al., 2011), and
decreased tryptophan levels in ASD patients with and without ID
(Boccuto et al., 2013).
It can be expected that future studies will report other defects
that may  commonly occur in subsets of ID and/or other cognitive
disorders. Drosophila models make a suitable and rather unlim-
ited “test cohort” to comprehensively replicate and validate such
ﬁndings, e.g. through biochemical approaches and metabolic mea-
surements in a large number of ID models. Drosophila experiments
can also provide direct evidence for the contribution of identiﬁed
signatures to a relevant phenotype.
4.4. Large-scale studies to identify novel ID networks and their
function
Drosophila is well suited to generate large comparative pheno-
typic datasets, because of the relative ease in which forward and
reverse genetic screens can be performed. In vivo screening pro-
vides additional beneﬁts over cell-based models, because complex
phenotypes such as cognition can be assayed.
Screens can be used to identify missing components in speciﬁc
processes or pathways, but they can also be used to obtain a broad
overview on function of a deﬁned group of insufﬁciently char-
acterized genes. Performing large-scale reverse genetic screens,
in combination with extensive phenotyping, could provide an
overview of the role of ID genes within the nervous system. In
addition, performing large-scale phenotyping analyses in model
organisms, compared to human patients, has several beneﬁts. First,
many of the conditions are rare, thus the small amount of patients
that can be investigated is limiting. Second, patients are usually
seen by different clinicians across various countries, which might
result in inconsistent clinical analysis between patients. Third, one
cannot control for genetic background and environmental fac-
tors in patients, whereas in model organisms such as Drosophila
the genetic background can be selected, and ﬂies can be raised
under controlled conditions. Combined, this keeps the inﬂuence
of variants other than the gene in question to a minimum. Thus,
comparative phenotyping approaches in model organisms should
be able to signiﬁcantly contribute to the identiﬁcation of evolution-
arily conserved genotype-phenotype correlations that are relevant
to human disorders.
Based on the widely recognized principle that identical or
similar phenotypes arise from disruptions of common processes,
comparative phenotyping approaches should be able to predict
novel gene functions and map  previously unappreciated functional
modules and pathways. A recent study reported an RNAi-based
candidate screen, targeting genes involved in a range of neurolog-
ical disorders, for defects in synaptic and mitochondrial function.
Loss of UbcD6,  the Drosophila ortholog of ID gene UBE2A,  induces
a number of phenotypes that, unexpectedly for its established role
in the nucleus, resembles defects found in Parkin mutants (Haddad
et al., 2013). This phenotypic resemblance is due to an overlap
in function: Drosophila UbcD6 has been demonstrated to act as
an E2 ubiquitin-conjugating enzyme that, in combination with
an E3 ubiquitin ligase such as Parkin, ubiquitinates mitochondrial
proteins to facilitate the clearance of dysfunctional mitochondria,
preventing neuronal dysfunction (Haddad et al., 2013). A sec-
ond study systematically targeted 270 ID gene orthologs in the
Drosophila eye (Oortveld et al., 2013). Assessment of neuronal
function in behavioral and electrophysiological assays and multi-
parametric morphological analysis assigned many novel functions
to ID genes, including a requirement in basal neurotransmission
for 16 ID genes that had not previously been implicated in this
process in any system or organism. Grouping genes by their pheno-
types identiﬁed 26 highly connected functionally coherent modules
that comprise a total of 100 ID genes and successfully predict addi-
tional gene functions such as a role in synapse/NMJ development.
Interestingly, Drosophila phenotype groups show, in addition to ID,
signiﬁcant phenotypic similarity also in humans, indicating that the
identiﬁed functional modules are conserved. This study provides a
ﬁrst overview of the modular architecture of ID and has presented
unbiased evidence for a long suspected broad functional coherence
underlying ID.
The indicated two studies pose the question whether RNAi is
an appropriate tool to model ID disorders. Whereas loss- versus
gain-of-function approaches in targeted studies should always be
tailored to the clinical condition of interest, an inventory reported
by Oortveld et al. revealed that for the vast majority of ID genes
(partial) loss-of-function is thought to be the causative mechanism
(Oortveld et al., 2013). This supports RNAi approaches as a suitable
approximation to the large group of human ID disorders. Future
systematic screens will address ID gene function in further disease-
relevant contexts.
5. Clinical application of Drosophila I: gene identiﬁcation
and diagnostics
Drosophila has been used to identify genetic interactors of dis-
ease genes. Such research frequently aims to deliver candidate
genes that can either modify the human disease phenotypes or
directly cause (the same or a similar) disease. While this approach
will remain valid, the need for candidate genes has become
obsolete. With the advent of next-generation sequencing, human
genetics generates more candidates than at present can be inter-
preted. Here, we  anticipate an increasing contribution of Drosophila
to the interpretation of genetic variants and their pathogenicity.
5.1. Challenges in gene identiﬁcation in the era of
next-generation sequencing
The advent of next-generation sequencing technology, which
allows interrogation of unlimited amounts of genomic informa-
tion with base-pair precise resolution, has begun to revolutionize
human genetics. A number of ID syndromes were among the ﬁrst
diseases genetically solved by applying this technology after exome
capture, including Schinzel-Giedion syndrome (SETBP1), Kabuki
syndrome (KMT2D), and Baraitser-Winter syndrome (ACTB and
ACTG1) (Hoischen et al., 2010; Ng et al., 2010a; Riviere et al.,
2012). Common to these three and further successful studies is that
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sequencing has been performed in a carefully selected, phenotyp-
ically coherent cohort of patients. This strategy strongly increases
the chances of ﬁnding the same gene to be affected in multiple
patients, thereby validating its causative nature. However, this
strategy cannot – or only to a minor extent – be applied to very rare,
phenotypically heterogeneous or even non-syndromic ID cohorts.
In many cases, suspicious variants are observed only in single
patients or families (de Ligt et al., 2012; Najmabadi et al., 2011;
Vissers et al., 2010). Furthermore, even considering only de novo
mutations, multiple potential disease-causing variants can be iden-
tiﬁed within a single patient. The primary challenge in such studies
has shifted from data analysis to interpretation, so as to distinguish
between background variants and pathogenic mutations. Currently
applied ﬁlters that identify potential causal variants among all vari-
ants detected are based on variant frequency, conservation scores,
predicted deleteriousness to protein structure, and if available,
evaluation of functional data of the affected gene (Ng et al., 2010b).
Surveys carried out on copy-number variations have demonstrated,
unsurprisingly for biologists, that functional information collected
in model organisms is particularly powerful (Hehir-Kwa et al.,
2010; Webber et al., 2009). The required functional data is available
however for only a minority of genes, such as non-systematically
acquired information on 5000 mouse genes. This limitation holds
particularly true if only considering information relevant to the
disease-relevant tissue(s), such as the nervous system for ID dis-
orders. The paucity of relevant functional data has become a major
bottleneck for the interpretation of variants in research and in rou-
tine diagnostics.
5.2. Guiding human genetics and clinical decision-making
through functional studies in Drosophila
Next-generation sequencing technology has already reached
diagnostics and in the following years is expected to become a
standard in medical genomics (Gonzaga-Jauregui et al., 2012). The
need for functional investigation of disease genes and variants can
safely be assumed to explode, at least (but probably not only) in
cases where human genetics/genomics will fail to detect recurrent
changes.
Can animal models contribute to routine diagnostics? We
believe so, but to overcome the bottleneck of lacking functional
data, extraordinarily efﬁcient model organisms are required that
permit the generation of relevant information in a short time and
on demand.
5.2.1. Support for causality through disease-relevant gene
function
Drosophila is in an excellent position to lend ad hoc support
to the causative nature of identiﬁed ID gene candidates that are
identiﬁed in diagnostics. Phenotypes that were previously reported
in ﬂy models of well-established ID disorders, such as synap-
tic, learning and memory defects, have been tested in a number
of Drosophila models of newly identiﬁed ID genes with various
degrees of (human) genetic evidence.
An ID gene that has received support for causality by vari-
ous Drosophila phenotypes including synaptic defects and learning
deﬁcits is CEP89,  a gene homozygously deleted in a single patient
with isolated complex IV deﬁciency, intellectual disability and mul-
tisystemic problems (van Bon et al., 2013). Other examples include
the combined approaches of heterozygosity mapping and next-
generation sequencing that led to the identiﬁcation of ANK3 and
NSUN2 as mutated in two forms of autosomal recessive ID. A bal-
anced translocation that disrupts one copy of all ANK3 isoforms in
one individual, and a homozygous mutation in the longest ANK3
isoform in a family were found. The causality of mutations in
ANK3 is supported by its previous implication in neuropsychiatric
disorders in humans and by Drosophila studies revealing a role
for this gene in synapse development (Koch et al., 2008; Pielage
et al., 2008) and memory (Iqbal et al., 2013). One  splice site and
two missense mutations were found in the RNA methyltransferase
NSUN2 gene in patients with autosomal recessive moderate to
severe ID and facial dysmorphism. The Nsun2 ﬂy model shows
severe defects in short-term memory in an olfactory conditioning
paradigm (Abbasi-Moheb et al., 2012).
More recently, candidates with genetic ﬁndings based on whole-
exome sequencing studies have been investigated in Drosophila.
Two loss-of-function mutations (a stop and frameshift) in the chro-
matin modiﬁer GATAD2B were found in exome studies (de Ligt et al.,
2012). These and further investigations showed that mutations
in GATAD2B cause a recognizable ID syndrome and are associ-
ated with learning deﬁcits and synaptic undergrowth in Drosophila
(Willemsen et al., 2013). Thus, rare genetic ﬁndings can signiﬁ-
cantly proﬁt from Drosophila models of their associated disorders.
5.2.2. Support for causality through disease-relevant gene-gene
interactions
Strong support for the causative involvement of a gene in a rec-
ognizable syndrome can also be provided by demonstrating genetic
interactions with an already established disease gene, or with fur-
ther novel candidates identiﬁed. This can make a sufﬁcient case
to reach a genetic diagnosis, even for genetic changes identiﬁed
in single patients, as has recently been demonstrated for Kleefstra
syndrome. In 2006, heterozygous deletions or mutations in EHMT1
were shown to cause this disorder (Kleefstra et al., 2006). However,
defects in EHMT1 are detected in only 25% of all patients with Kleef-
stra syndrome, strongly suggesting the involvement of additional
genes (Kleefstra et al., 2009). By targeted approaches and exome
sequencing, de novo mutations in ﬁve genes were found in four
patients with the core features of Kleefstra syndrome (Kleefstra
et al., 2012). These genes were MLL3, MDB5,  SMARCB1, NR1I3 and
MTMR9; the latter two  genes carried mutations in the same patient.
Sequencing these genes in an additional cohort of 50 patients
did not reveal additional mutations. Therefore, although it was
immediately striking that four of these genes, like EHMT1,  encode
regulators of chromatin, the causality of these mutations remained
to be demonstrated. Available information and pairwise genetic
interaction experiments with Drosophila EHMT in the wing allowed
for the reconstruction of a novel chromatin modiﬁcation mod-
ule with both synergistic and antagonistic interactions (Kleefstra
et al., 2012). Furthermore, a genetic interaction was found between
EHMT and the ortholog of NR1I3,  but not between EHMT and
Drosophila MTMR9. The absence of the latter interaction contributed
to the individual’s diagnosis of a causative mutation in the nuclear
receptor gene. This shows that Drosophila phenotyping can inform
human genetics, and facilitate clinical decision-making. Of  note,
clinical syndromes being genetically heterogeneous is a rule rather
than an exception (Oti and Brunner, 2007). This approach is there-
fore widely applicable.
5.2.3. Analysis of variants
Finally, disease-relevant biological assays to directly assess
the effect of a disease allele/variant are desirable (Zaghloul and
Katsanis, 2010). However, constructs and transgenic ﬂies for such
an approach have to be generated, making it more time-consuming
than loss or gain of function studies using available resources such
as genome-wide inducible RNAi collections and overexpression
stocks. Variants can be investigated in overexpression experiments,
comparing gain-of-function phenotypes evoked by the wild-type
allele to those caused by mutant alleles. This approach has been
used in the early days in ﬂy models of Fragile X syndrome to
determine the consequence of a rare FMR1 point mutation, l367N,
located in the second KH (RNA-binding) domain (Wan  et al., 2000).
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Analogous mutations introduced in either the KH1 or KH2 domain
of the Drosophila ortholog signiﬁcantly ameliorates, but does not
completely suppress external and internal eye defects, demonstrat-
ing that this allele represents a partial loss-of-function allele.
Re-expression strategies to rescue a null condition with wild-
type versus mutant constructs, gene replacement strategies or
genome editing, are more advanced approaches that can be used to
address the particular function of an observed variant of interest.
Over- and re-expression approaches can express the human gene
and variants, or the ﬂy gene with introduced variant, if the affected
amino acid is conserved (Coffee et al., 2012).
6. Clinical application of Drosophila II: toward treatment
6.1. From reversible phenotypes in models of ID to ﬁrst clinical
trials
ID disorders have long been thought to result from abnormal
brain development rather than from acute deﬁcits in neuronal
function, because brain function in ID patients is affected at or
soon after birth. They have thus been considered untreatable.
However, an accumulating body of evidence demonstrates that
behavioral and cognitive phenotypes in several animal models of
ID disorders can be improved or restored at post-embryonic stages.
Genetic and/or pharmacologic rescue in adulthood was  success-
ful in mouse models of Neuroﬁbromatosis (NF1), Rett syndrome
(MECP2), Rubinstein-Taybi (CBP), Macrocephaly/Autism syndrome
(PTEN), Angelman syndrome (UBE3A) and Tuberous sclerosis (TSC1
and TSC2), reviewed elsewhere (Castrén et al., 2012; Ehninger et al.,
2008). After the early ﬁnding that statins, widely used cholesterol-
lowering drugs applied to treat hypercholesterolemia, improved
learning and attention deﬁcits in the NF1 mouse model (Li et al.,
2005), it took only three years until the ﬁrst report of a random-
ized, controlled trial came out (Krab et al., 2008a). The challenges
associated with translating such trials and ﬁndings to humans are
discussed in (Castrén et al., 2012). Researchers of the Learning Dis-
abilities Network (LeaDNet) and the expertise center ENCORE at
the Erasmus Medical Center (Rotterdam, Netherlands) have estab-
lished competence to facilitate and conduct further clinical trials in
Neuroﬁbromatosis type 1 and other “reversible” ID disorders men-
tioned previously, notably those associated with the Ras/MAPK and
mTOR pathways (Acosta et al., 2012; ENCORE).
Despite these encouraging activities and the impact that they
have on our view of the molecular nature and temporal origin of
(at least some) ID disorders, work in this ﬁeld is still limited. Two
bottlenecks that limit the expansion of investigations in this ﬁeld
are: (1) identifying ID disorders in which behavioral and cognitive
deﬁcit can potentially be restored, and (2) identifying compounds
that can serve as a starting point for clinical trials. Animal models,
to date primarily mice, have been indispensable in gathering the
knowledge necessary to initiate the ﬁrst steps toward treatment
described above. However, generation of mutant mouse models
and breeding takes considerable time and resources, and therefore
typically only up to a hand-full of compounds are tested, at least in
academic settings. Drosophila models are ideally suited as an initial
tool to determine by genetic approaches whether cognitive or other
disease-relevant defects can be rescued by adult re-expression of
a gene in a mutant background, and for targeted drug testing.
Moreover, ﬂies can be effectively used for drug screens, much as
the traditional high-throughput screens in pharmaceutical industry
that are based on in vitro cell culture or biochemical assays.
Drosophila has made a major contribution to the identiﬁcation
of pharmacological rescue in Fragile X syndrome. Following the
mGluR theory of Fragile X, successful treatment of phenotypes
including learning and memory defects with mGluR5 antagonists
and lithium was ﬁrst accomplished in the Fragile X ﬂy model (Bear
et al., 2004; McBride et al., 2005). In subsequent years, these com-
pounds have proven to counteract behavioral, morphological and
neurophysiological abnormalities in mutant mice and are currently
being tested in clinical trials (Choi et al., 2011; de Vrij et al., 2008;
Yan et al., 2005). Signiﬁcant improvement of abnormal behaviors
associated with the disease has been reported, at least in a subgroup
of patients (Berry-Kravis et al., 2008; Jacquemont and Curie, 2011).
Further studies are required, particularly with carefully assessed
cognitive outcome measures.
In addition to the targeted approach, an unbiased drug screen
has been carried out in Fragile X ﬂies (Chang et al., 2008). Inter-
estingly, three of the compounds that rescued Fragile X-related
glutamate-induced lethality were positive regulators of GABA
signaling. This made immediate sense, since the GABAergic sys-
tem counteracts glutamatergic excitatory circuits that are overly
active in Fragile X syndrome. This ﬁnding is also in agreement with
previous reports on reduced expression of several GABA-A receptor
subunits, consistently found in the Fragile X mouse and Drosophila
models (D’Hulst et al., 2006; El Idrissi et al., 2005). GABA-A recep-
tor agonists have subsequently revealed beneﬁcial effects in mice.
Ganaxolone is currently in phase II clinical trials for the treatment
of epilepsy and is thus also a promising treatment option for Fragile
X patients (Heulens et al., 2012).
The most recently reported successful adult rescue of a ID dis-
order has been accomplished in the earlier-mentioned Drosophila
model of Kleefstra syndrome. Re-expression of EHMT from a trans-
gene, induced in adult ﬂies, fully restores memory (Kramer et al.,
2011). The epigenetic function and genetic interactions between
EHMT and other Kleefstra syndrome genes (Kleefstra et al., 2012)
provide a lead for future drug testing.
6.2. Disease-relevant outcome measures for high-throughput
drug screens
When it comes to unbiased testing of chemical compounds,
Drosophila offers advantage over classic in vitro screens pursued
by pharmaceutical companies that traditionally have a very high
rate of failure late in the drug development process. Optimized lead
compounds often turn out to be toxic to the complex physiology of
an intact organism, or fail to exhibit the desirable characteristics
for absorption, distribution, metabolism and/or excretion (ADME
properties) (Pandey and Nichols, 2011). Despite their evolutionary
distance to humans, it is likely that Drosophila models can offer
complementary, if not better, information on physiological bene-
ﬁts and side effects of drugs than in vitro systems. As in humans,
the output measure of drug screens in ﬂy (and other animal) mod-
els is likely to be a parameter of great importance for success. The
encouraging ﬁndings of the drug screen in Fragile X ﬂies shows
that even lethality can be used as read-out in a primary screen,
however it should be kept in mind that not every ID gene is essen-
tial or can be sensitized to lethality as in this speciﬁc case (Chang
et al., 2008). More sophisticated output measures that are directly
related to the disease pathology, such as learning or memory, are
desirable. This may  reduce the throughput of a screen to a certain
degree. However, genetic screens for learning and memory mutants
have been performed for decades in Drosophila and novel high-
throughput compatible solutions are emerging, from automated
tracking of ﬂy behavior (Dankert et al., 2009; Dubnau and Tully,
1998; Skoulakis and Grammenoudi, 2006; Valente et al., 2007) to
complete (commercially available) set-ups such as Aktogen’s Auto-
jump system (Sharma et al., 2009). Testing mutant conditions in a
similar paradigm, Drosophila light-off jump habituation has already
revealed defects in non-associative learning in several Drosophila
models of ID (Kramer et al., 2011; van Bon et al., 2013; Willemsen
et al., 2013). It is to be hoped that such solutions will ultimately be
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adopted by the pharmaceutical industry in academic and private
partnerships to advance drug testing for ID and related disorders.
6.3. Summary and future direction: “network medicine”
It appears unrealistic to speculate, based on a dozen studies
in animal models (Castrén et al., 2012; Ehninger et al., 2008),
that cognitive deﬁcits can be potentially reversed in the majority
of ID disorders. Yet, the previously listed ﬁndings are intriguing
and raise hope that a signiﬁcant number of such conditions exist.
Likewise, it seems unlikely that cognitive impairment in humans
can be cured, and we therefore believe that this term should
be avoided not to raise expectations above the realistic. How-
ever, treatment that helps to improve cognitive and/or behavioral
functioning, potentially in combination with environmental stimu-
lation, would represent a major step forward for patients and their
families (Castrén et al., 2012). Great effort should thus be invested
in better understanding the molecular neurobiology that underlies
individual or groups of ID disorders and in the translation of such
knowledge to the clinics.
Despite the socio-economic importance of ID and its high preva-
lence in the general population, the vast majority of ID disorders
are rare, in fact too rare to receive attention from the pharmaceuti-
cal industry. Therefore, it is to be expected that academic research,
patient foundations and public funding have to drive progress in
this ﬁeld. Because of the immense costs of developing new drugs,
testing/screening drugs that are already FDA-approved appears
to be the most promising road forward at present. Moreover,
accumulating insights into molecular mechanisms that are shared
among ID disorders can be envisioned to provide the opportunity
to target genetically heterogeneous patients with a common treat-
ment. Such shared mechanisms can represent either compromised
molecular networks, or more broadly compromised molecular pro-
cesses. For example, among ID disorders there are at least a dozen
genetic conditions that are due to mutations in components or
regulators of the mitochondrial oxidative phosphorylation machin-
ery. Oxidative phosphorylation is also affected in additional ID
disorders (Haddad et al., 2013; Kriaucionis et al., 2006; van Bon
et al., 2013), making approaches to improve or bypass defects in
this process an attractive common theme for treatment. Molecular
networks – signaling pathways or other protein–protein interac-
tion modules – can likewise provide a common ground to target
multiple conditions. The above discussed chromatin modiﬁcation
module underlying Kleefstra spectrum disorders and Rasopathies
are only some examples. The ﬁrst large-scale functional approach to
ID in Drosophila has identiﬁed 26 phenotypically coherent modules
(phenoclusters) using morphological eye and functional pheno-
typing. Interestingly, a validated cluster of eight ID genes has
successfully predicted novel roles in synapse development for three
of these genes. This cluster also includes PTEN and TSC2, two ID
genes whose associated cognitive defects are reversible, making the
six other genes in the same cluster (MYO5A, MYCN,  RPS6KA3, DMD,
PIGV and UPF3B),  prime candidates for cognitive proﬁling, adult res-
cue experiments and, if successful, drug trials (Oortveld et al., 2013).
Drosophila research is likely to contribute to such efforts.
7. From modeling monogenic forms of ID to modeling
oligogenic ID and multifactorial cognitive disorders
7.1. Cognitive disorders of multifactorial inheritance
7.1.1. Emerging evidence for oligogenic ID
The identiﬁcation of genes for ID has been most success-
ful for disorders that display a monogenic inheritance pattern,
many of which have been identiﬁed by genetic linkage in large
consanguineous families. A large number of cases remain unsolved,
but with the recent advent of exome sequencing, many cases of
sporadic ID have been found to be monogenic as well, with a sig-
niﬁcant contribution of de novo mutations (Ku et al., 2013; Veltman
and Brunner, 2012; Vissers et al., 2010). However, not all cases of
ID display monogenic patterns of inheritance. Whereas severe de
novo mutations are often limiting fecundity and thus remain rare
in populations, weaker mutations can be more common and result
in more complex inheritance patterns (de Ligt et al., 2012; Rauch
et al., 2012).
Exome sequencing, and probably soon whole-genome sequenc-
ing, provide new opportunities – and enormous challenges – in
uncovering complex patterns of inheritance underlying a fraction
of ID disorders. Particularly in the mild spectrum of ID (IQ ∼50–70),
an oligogenic or multifactorial inheritance is likely much more fre-
quent than currently appreciated and may  account for a signiﬁcant
proportion of still unsolved cases of ID. For instance Bardet-Biedl
syndrome, which is associated with ID, is inherited in a classic
recessive pattern, but di- and trigenic inheritance has been demon-
strated in some cases (Katsanis et al., 2001). In total 15 genes
have been identiﬁed of which different combinations were found
to segregate in families (Badano et al., 2006; Beales et al., 2003;
Billingsley et al., 2010; Bin et al., 2009; Chen et al., 2011; Fauser
et al., 2003; Hjortshøj et al., 2010; Katsanis et al., 2002). Other exam-
ples of ID disorders with partly complex inheritance are Dent’s
disease (co-inheritance of OCRL and CLCN5 mutations) (Addis et al.,
2013), Holoprosencephaly (SHH with either ZIC2 or TGIF1) (Ming
and Muenke, 2002; Nanni et al., 1999), Rasopathy (PTPN11 and
SOS1) (Fahrner et al., 2012) and other forms of ID (MECP2 and ATRX;
SHANK2 and CHRNA7; NRXN1 and various) (Béna et al., 2013; Chilian
et al., 2013; Honda et al., 2012; Leblond et al., 2012), or ID with
co-morbid ASD (FOXP1 and CNTNAP2) (O’Roak et al., 2011).
These examples illustrate that genes that have so far been
implicated in oligogenic ID are, with few exceptions, identical to
monogenic ID genes. This suggests that it is not the genes but
the strength of particular mutations that dictate whether addi-
tional factors are required for disease presentation. The above
listed examples also illustrate that oligogenic inheritance is based
on gene-gene interactions that occur among genes that act in
the same molecular network. While striking in the gene pairs
reported above, (e.g. OCRL and CLCN5 are implicated in endocy-
tosis (Devuyst et al., 1999; Erdmann et al., 2007), ZIC2 and TGIF1
interfere with SHH signaling (Ming and Muenke, 2002; Nanni et al.,
1999), PTPN11 and SOS1 both act in Ras/MAPK signaling pathways
(Fahrner et al., 2012), MECP2 and ATRX chromatin proteins directly
interact with each other (Nan et al., 2007), CNTNAP2 is a target
gene of FOXP1 (O’Roak et al., 2011)), the extent to which these two
themes will apply in general is unknown. At present the ﬁeld of
oligogenic inheritance is strongly dependent on hypothesis-driven
data interpretation based on exactly these two  themes (known dis-
ease associations and functional connections between candidates).
The current view is surely highly biased.
Gene-gene interactions and additive effects are also likely to be
contributing to neuropathology caused by copy-number variations,
which also play a prominent role in ID. Our current knowledge of
oligogenic causes of ID may  only represents the tip of the iceberg.
This scenario resembles the complexity and challenges of unravel-
ing the genetics of neuropsychiatric disorders.
7.1.2. Genetic overlap between ID and neuropsychiatric disorders
Not only do some ID disorders share a oligogenic etiology with
neuropsychiatric disorders, they also appear to (partly) share their
underlying genetic architecture. The genetic overlap may  in part be
the result of the same pathogenic genes, but different genetic aber-
rations. While individual ID disorders are rare in the population,
neuropsychiatric disorders are common. The most common cause
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Fig. 3. Genetic overlap of ID and neuropsychiatric disorders. Monogenic disorders
often arise from rare mutations that have a severe impact on gene function, while
multifactorial disorders often arise from common variants with a weaker severity.
PTHS, Pitt-Hopkins syndrome; AS, Angelman syndrome; KS, Kleefstra syndrome;
FraX, Fragile X syndrome; BBS, Bardet-Biedl syndrome; NS, Noonan syndrome;
ASD,  Autism spectrum disorder; SCZ, Schizophrenia; BP, Bipolar disorder; ADHD,
attention-deﬁcit/hyperactivity disorder; MDD, major depressive disorder.
of inherited ID is Fragile X syndrome and occurs in 1/5000 males,
while attention-deﬁcit/hyperactivity disorder (ADHD) is diagnosed
in 13% of boys. Interestingly, ADHD is one of the most frequently
recognized disorders associated with Fragile X syndrome: 54–59%
of boys with Fragile X syndrome meet diagnostic behavioral crite-
ria for ADHD (Sullivan et al., 2006). It is intriguing to consider that
similar pathways are disturbed in Fragile X and ADHD. While Frag-
ile X is a disorder with a severe mutation in a single gene, ADHD is
hypothesized to be the accumulated effect of multiple weaker gene
variations (Fig. 3).
Multifactorial disorders overlap in their genetics as well, as
shown for childhood ADHD and adult Schizophrenia, or suggested
by the recent cross-disorder study that reported shared genetic
relationship between ﬁve major psychiatric disorders (Psychiatric
Genomics Consortium et al., 2013; Hamshere et al., 2013). As is rec-
ognized at the start of the DSM-5 (Adam, 2013) and by the NIMH
Research Domain Criteria project (Morris and Cuthbert, 2012), psy-
chiatric disorders should be seen as dimensional traits that share
biological overlap rather than being classiﬁed as distinct groups.
Environment and genetic modiﬁers can signiﬁcantly modulate the
ﬁnal disease presentation.
Gene identiﬁcation studies for complex genetic or multifacto-
rial disorders still greatly lag behind classical Mendelian ones, but a
strong genetic component has been established for many neuropsy-
chiatric disorders through twin and adoption studies. For example,
the heritability of the relatively common ASD is estimated to be
90% and ADHD 75–90% (Elia et al., 2012; Faraone et al., 2005; Wood
et al., 2008), but the identiﬁcation of genetic factors is not straight-
forward, resulting in the concept of missing heritability (Bailey
et al., 1995; Elia et al., 2012; Faraone et al., 2005; Manolio et al.,
2009; Wood et al., 2008). The mutations underlying these disor-
ders are thought to have a small effect size and be common in the
population, making their identiﬁcation a challenge.
Nonetheless research has been successful in uncovering impor-
tant genetic factors for presumably multifactorial traits. This
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Fig. 4. Publications reporting Drosophila models of neurodegenerative, intellectual
disability, and neuropsychiatric disorders. Publications mentioning Drosophila mod-
els  of neurodegenerative disorders have increased linearly over the past decade,
while ID models have taken off since 2007 after a preceding wave of reviews. In
recent years the modeling of neuropsychiatric disorders is receiving increasing
attention.
applies to ADHD-like characteristics that are comorbid with a wide
variety of monogenic ID disorders such as Fragile X syndrome,
Tuberous Sclerosis, Neuroﬁbromatosis I and other Rasopathies, and
multigenic ID conditions such as Williams Syndrome (Curatolo
et al., 2009). Additionally, autistic traits are often co-morbid with
monogenic ID disorders such as Fragile X syndrome or Tuberous
Sclerosis (Zafeiriou et al., 2007). Modeling monogenic ID to under-
stand their molecular/cellular/developmental basis is thus likely to
provide insights into oligogenic forms of ID and into other neu-
ropsychiatric disorders. Drosophila is an excellent model system
to study complex genetic interactions that underlie multifactorial
disorders, because of its strength in combinatorial genetics and the
wide range of established behavioral paradigms.
7.2. Drosophila as a model for multifactorial cognitive disorders
Modeling neuropsychiatric disorders in Drosophila stands now
where modeling of ID was around 10 years ago: its successful appli-
cation is still very limited, but it is receiving increasing attention.
Drosophila models of neuropsychiatric disorders are increasingly
discussed in the literature although these are, at present, more
reviews than research papers (van Alphen and van Swinderen,
2011), just as it was the case in the ﬁrst years of this millennium
for ID (see Fig. 4). Many opportunities and challenges in this ﬁeld
lie ahead.
When variants in multiple genes are identiﬁed in oligogenic
forms of ID and psychiatric genetics, it is hard to prove the causative
nature of the mutations. The families often show incomplete pen-
etrance, or multiple combinations segregate. Drosophila provides
the excellent opportunity to perform gene-gene/protein-protein
interaction studies, which can test the hypothesis of the oligogenic
inheritance found in humans. Of note, such experiments can be car-
ried out under conditions that control for genetic background and
environmental factors, reducing the impact of confounding factors
on the phenotype.
An example of uncovering a protein-protein interaction
involved in both ID and neuropsychiatric disorder is the E3 ubiqui-
tin ligase protein UBE3A, which is mutated in Angelman syndrome
and overexpressed in 15q duplication Autism. A proteomic screen
in Drosophila revealed that Ube3a regulates the actin cytoskeleton
and neuronal homeostasis. Ube3a was found to ubiquitinate the
Autism-associated Na+/K+ pump ATP, stimulating new avenues
of research in ﬂy and mouse models of Angelman syndrome and
Autism (Jensen et al., 2013).
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In few cases monogenic heritable neuropsychiatric disor-
ders have been studied in Drosophila,  such as disrupted-in-
schizophrenia-1 (DISC1), one of the major susceptibility factors for
a wide range of mental illnesses, including Schizophrenia, Bipo-
lar Disorder, Major Depression and Autism Spectrum conditions
(Sawamura et al., 2008). Expression of human DISC1 in Drosophila
results in punctate localization of the protein in the nucleus, which
was validated in primary mammalian neuron cultures. The trans-
genic ﬂies display defects of sleep homeostasis consistent with
altered CREB signaling. Indeed, DISC1 was found to modulate CRE-
mediated gene transcription through interaction with ATF4/CREB2.
Screening for genetic interactors that normalize or enhance the
DISC1-induced sleep alteration would be of great interest.
Misregulation of the ortholog of the Schizophrenia suscepti-
bility gene dysbindin (DTNBP1) revealed its regulatory function
of glutamatergic and dopaminergic signaling, and with genetic
tools exclusively available in Drosophila,  two independent mecha-
nisms could be identiﬁed that lead to clinically relevant behavioral
phenotypes (Shao et al., 2011). First, reduced expression of dys-
bindin in presynaptic neurons suppresses glutamatergic synaptic
transmission, which results in impaired memory. Second, reduced
expression of dysbindin in glial cells causes hyperdopaminergic
activities that lead to abnormal locomotion. Both behaviors can
be rescued with acute genetic or pharmacological treatments in
adults, suggesting that genetically relevant phenotypes in humans
could be reversible.
Neuroligins have been implicated in ID and ASDs, together with
several other components (Neurexins and Shanks) of the trans-
synaptic signaling machinery. Deletion of Drosophila Neuroligin 2
impairs social interactions, alters acoustic communication signals,
and affects the transition between different behaviors, resembling
some core symptoms of ASDs (Hahn et al., 2013).
To facilitate translational research including drug testing, it
would be an important achievement to develop or optimize behav-
ior assays that parallels mouse and human behavior as closely as
possible, yet can be conducted in higher throughput. For oligogenic
disorders it will be important (compared to successful monogenic
ID models) to be able to control efﬁciency of gene manipulation
more tightly and to apply highly sensitive assays. Not necessar-
ily, but ideally, such assays would test speciﬁc cognitive domains
and recapitulate selective aspects of behavioral problems seen in
the disorders. The spectrum of behaviors that can be assayed in
Drosophila is constantly increasing. These include non-associative
and associative learning and memory, social behavior, aggression,
social interaction, decision-making, activity and sleep, and addic-
tion (Anholt and Mackay, 2012; Billeter and Levine, 2013; Davis,
2011; Harbison et al., 2009; Maimon et al., 2008; Ojelade and
Rothenﬂuh, 2009; Pavlou and Goodwin, 2013; Sokolowski, 2010).
Modeling neuropsychiatric disorders in Drosophila is still in its
infancy, but it can be anticipated that such neuropsychiatric models
will ‘ﬂy off’ soon.
8. Concluding remarks
With this review, we have aimed to provide an overview on
the contribution that Drosophila research has made to date to
our understanding of ID disorders and of the molecular control
of cognition. Bridging the gap between fundamental and clinical
research is of high important and societal signiﬁcance as it can
speed up scientiﬁc and medical progress. Researchers studying
Drosophila and human biology can proﬁt greatly from mutualisms:
phenotypes of human conditions can indicate similar underlying
pathologies to be investigated in Drosophila,  while on the other
hand clinical researchers can greatly beneﬁt from the fundamental
knowledge that has been acquired in the past century in Drosophila
(Bellen et al., 2010). However, mutualism requires awareness of
knowledge/publications in both ﬁelds, which is not always straight-
forward when genes are named differently across species. The
Ensembl genome browser (www.ensembl.org) functions as a broad
platform and has a great resource for quick retrieval of orthologs,
using the comparative genomics pages that utilize phylogenetic
trees to cluster homologs (Flicek et al., 2013). Orthologs can be
found in the Ensembl gene-based display, or retrieved through
a BioMart query (Vilella et al., 2009). Reversely, the database
of Drosophila genes and genomes (FlyBase, www.ﬂybase.org) has
recently implemented an orthology section (Marygold et al., 2013)
that makes it easy for Drosophila researchers to identify human
orthologs. The FlyBase gene summary pages also contain gene
function and phenotype summaries and publication lists that are
informative for human geneticists and clinicians.
Here, we focused on the opportunities, not limitations, that we
see and predict for Drosophila as a model, particularly for transla-
tional research in future medical genomics. It is not our opinion
that Drosophila is superior to other genetic model organisms such
as worm,  zebraﬁsh and mouse. On the contrary, particularly ver-
tebrate models provide an important and indispensable bridge to
translate the insights gained in Drosophila into future applications
that will improve diagnosis, personalized patient support and treat-
ment.
Acknowledgements
We thank J.M. Kramer, A.P. de Brouwer, R. Evans and H. van
Bokhoven for critical reading of the manuscript. Our research is
supported by a Brain and Cognition Excellence Program grant (433-
09-229), VIDI and TOP grants (917-96-346, 912-12-109) from the
Netherlands Organization for Scientiﬁc Research (NWO), by an
NCMLS/Radboud university medical center fellowship, by the Ger-
man  Mental Retardation Network funded by the NGFN+ program
of the German Federal Ministry of Education and Research (BMBF)
and by the European Union’s FP7 large scale integrated network
Gencodys (HEALTH-241995).
References
Abbasi-Moheb, L., Mertel, S., Gonsior, M.,  Nouri-Vahid, L., Kahrizi, K., Cirak, S.,
Wieczorek, D., Motazacker, M.M.,  Esmaeeli-Nieh, S., Cremer, K., Weißmann, R.,
Tzschach, A., Garshasbi, M.,  Abedini, S.S., Najmabadi, H., Ropers, H.H., Sigrist, S.J.,
Kuss, A.W., 2012. Mutations in NSUN2 cause autosomal-recessive intellectual
disability. Am.  J. Hum. Genet. 90, 847–855.
Acosta, M.T., Bearden, C.E., Castellanos, F.X., Castellanos, X.F., Cutting, L., Elgersma,
Y.,  Gioia, G., Gutmann, D.H., Lee, Y.-S., Legius, E., Muenke, M., North, K., Parada,
L.F., Ratner, N., Hunter-Schaedle, K., Silva, A.J., 2012. The learning disabilities
network (LeaDNet): using neuroﬁbromatosis type 1 (NF1) as a paradigm for
translational research. Am.  J. Med. Genet. A 158A, 2225–2232.
Adam, D., 2013. Mental health: on the spectrum. Nature 496, 416–418.
Addis, M., Meloni, C., Tosetto, E., Ceol, M., Cristofaro, R., Melis, M.A., Vercelloni, P.,
Del Prete, D., Marra, G., Anglani, F., 2013. An atypical Dent’s disease phenotype
caused by co-inheritance of mutations at CLCN5 and OCRL genes. Eur. J. Hum.
Genet. 21, 687–690.
Alves-Sampaio, A., Troca-Marin, J.A., Montesinos, M.L., 2010. NMDA-mediated reg-
ulation of DSCAM dendritic local translation is lost in a mouse model of Down’s
syndrome. J. Neurosci. 30, 13537–13548.
American Psychiatric Association, 1994. The Diagnostic and Statistical Manual of
Mental Disorders (DSM), fourth ed. (DSM-IV).
Amiel, J., Rio, M.,  de Pontual, L., Redon, R., Malan, V., Boddaert, N., Plouin, P.,
Carter, N.P., Lyonnet, S., Munnich, A., Colleaux, L., 2007. Mutations in TCF4,
encoding a class I basic helix-loop-helix transcription factor, are responsible
for  Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with
autonomic dysfunction. Am.  J. Hum. Genet. 80, 988–993.
Anderson, G.R., Galﬁn, T., Xu, W.,  Aoto, J., Malenka, R.C., Sudhof, T.C., 2012. Candidate
autism gene screen identiﬁes critical role for cell-adhesion molecule CASPR2 in
dendritic arborization and spine development. Proc. Natl. Acad. Sci. U.  S. A. 109,
18120–18125.
Anholt, R.R.H., Mackay, T.F.C., 2012. Genetics of aggression. Ann. Rev. Genet. 46,
145–164.
M. van der Voet et al. / Neuroscience and Biobehavioral Reviews 46 (2014) 326–342 339
Badano, J.L., Leitch, C.C., Ansley, S.J., May-Simera, H., Lawson, S., Lewis, R.A., Beales,
P.L., Dietz, H.C., Fisher, S., Katsanis, N., 2006. Dissection of epistasis in oligogenic
Bardet-Biedl syndrome. Nature 439, 326–330.
Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., Rutter, M.,
1995. Autism as a strongly genetic disorder: evidence from a British twin study.
Psychol. Med. 25, 63–77.
Balemans, M.C., Kasri, N.N., Kopanitsa, M.V., Aﬁnowi, N.O., Ramakers, G., Peters, T.A.,
Beynon, A.J., Janssen, S.M., van Summeren, R.C., Eeftens, J.M., Eikelenboom, N.,
Benevento, M.,  Tachibana, M.,  Shinkai, Y., Kleefstra, T., van Bokhoven, H., Van der
Zee, C.E., 2013. Hippocampal dysfunction in the Euchromatin histone methyl-
transferase 1 heterozygous knockout mouse model for Kleefstra syndrome.
Hum. Mol. Genet. 22, 852–866.
Beales, P.L., Badano, J.L., Ross, A.J., Ansley, S.J., Hoskins, B.E., Kirsten, B., Mein, C.A.,
Froguel, P., Scambler, P.J., Lewis, R.A., Lupski, J.R., Katsanis, N., 2003. Genetic
interaction of BBS1 mutations with alleles at other BBS loci can result in non-
mendelian Bardet-Biedl syndrome. Am.  J. Hum. Genet. 72, 1187–1199.
Bear, M.F., Huber, K.M., Warren, S.T., 2004. The mGluR theory of fragile X mental
retardation. Trends Neurosci. 27, 370–377.
Bellen, H.J., Tong, C., Tsuda, H., 2010. 100 years of Drosophila research and its impact
on  vertebrate neuroscience: a history lesson for the future. Nat. Rev. Neurosci.
11, 514–522.
Béna, F., Bruno, D.L., Eriksson, M.,  van Ravenswaaij-Arts, C., Stark, Z., Dijkhuizen, T.,
Gerkes, E., Gimelli, S., Ganesamoorthy, D., Thuresson, A.C., Labalme, A., Till, M.,
Bilan, F., Pasquier, L., Kitzis, A., Dubourgm, C., Rossi, M., Bottani, A., Gagnebin,
M.,  Sanlaville, D., Gilbert-Dussardier, B., Guipponi, M.,  van Haeringen, A., Kriek,
M.,  Ruivenkamp, C., Antonarakis, S.E., Anderlid, B.M., Slater, H.R., Schoumans,
J., 2013. Molecular and clinical characterization of 25 individuals with exonic
deletions of NRXN1 and comprehensive review of the literature. Am.  J. Med.
Genet. B Neuropsychiatry Genet. 162, 388–403.
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M.,  Porges, S.W., Weng, N., Weiler,
I.J.,  Greenough, W.T., 2008. Open-label treatment trial of lithium to target the
underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 29, 293–302.
Bier, E., 2005. Drosophila, the golden bug, emerges as a tool for human genetics. Nat.
Rev. Genet. 6, 9–23.
Billeter, J.-C., Levine, J.D., 2013. Who  is he and what is he to you? Recognition in
Drosophila melanogaster. Curr. Opin. Neurobiol. 23, 17–23.
Billingsley, G., Bin, J., Fieggen, K.J., Duncan, J.L., Gerth, C., Ogata, K., Wodak, S.S., Tra-
boulsi, E.I., Fishman, G.A., Paterson, A., Chitayat, D., Knueppel, T., Millán, J.M.,
Mitchell, G.A., Deveault, C., Héon, E., 2010. Mutations in chaperonin-like BBS
genes are a major contributor to disease development in a multiethnic Bardet-
Biedl syndrome patient population. J. Med. Genet. 47, 453–463.
Bin, J., Madhavan, J., Ferrini, W.,  Mok, C.A., Billingsley, G., Héon, E., 2009. BBS7 and
TTC8 (BBS8) mutations play a minor role in the mutational load of Bardet-Biedl
syndrome in a multiethnic population. Hum. Mutat. 30, E737–E746.
Boccuto, L., Chen, C.-F., Pittman, A.R., Skinner, C.D., McCartney, H.J., Jones, K., Bochner,
B.R., Stevenson, R.E., Schwartz, C.E., 2013. Decreased tryptophan metabolism in
patients with autism spectrum disorders. Mol. Autism 4, 16.
Bolduc, F.V., Tully, T., 2009. Fruit ﬂies and intellectual disability. Fly (Austin) 3,
91–104.
Brand, A.H., Perrimon, N., 1993. Targeted gene expression as a means of altering cell
fates and generating dominant phenotypes. Development 118, 401–415.
Brockschmidt, A., Todt, U., Ryu, S., Hoischen, A., Landwehr, C., Birnbaum, S., Frenck,
W.,  Radlwimmer, B., Lichter, P., Engels, H., Driever, W.,  Kubisch, C., Weber, R.G.,
2007. Severe mental retardation with breathing abnormalities (Pitt-Hopkins
syndrome) is caused by haploinsufﬁciency of the neuronal bHLH transcription
factor TCF4. Hum. Mol. Genet. 16, 1488–1494.
Brown, V., Jin, P., Ceman, S., Darnell, J.C., O’Donnell, W.T., Tenebaum, S.A., Jin, X.,
Wilkinson, K.D., Keene, J.D., Darnell, R.B., 2001. Microarray identiﬁcation of
FMRP-associated brain mRNAs and altered mRNA translational proﬁles in fragile
X  syndrome. Cell 107, 12–20.
Bushey, D., Tononi, G., Cirelli, C., 2011. Sleep and synaptic homeostasis: structural
evidence in Drosophila. Science 332, 1576–1581.
Castets, M.,  Schaeffer, C., Bechara, E., Schenck, A., Khandjian, E.W., Luche, S., Moine,
H.,  Rabilloud, T., Mandel, J.L., Bardoni, B., 2005. FMRP interferes with the Rac1
pathway and controls actin cytoskeleton dynamics in murine ﬁbroblasts. Hum.
Mol.  Genet. 14, 835–844.
Castrén, E., Elgersma, Y., Maffei, L., Hagerman, R., 2012. Treatment of neurodevelop-
mental disorders in adulthood. J. Neurosci. 32, 14074–14079.
Caudy, A.A., Myers, M.,  Hannon, G.J., Hammond, S.M., 2002. Fragile X-related protein
and  VIG associate with the RNA interference machinery. Genes Develop. 16,
2491–2496.
Caudy, M.,  Grell, E.H., Dambly-Chaudiere, C., Ghysen, A., Jan, L.Y., Jan, Y.N., 1988.
The maternal sex determination gene daughterless has zygotic activity neces-
sary for the formation of peripheral neurons in Drosophila. Genes Develop. 2,
843–852.
Chang, S., Bray, S.M., Li, Z., Zarnescu, D.C., He, C., Jin, P., Warren, S.T., 2008. Identiﬁca-
tion of small molecules rescuing fragile X syndrome phenotypes in Drosophila.
Nat. Chem. Biol. 4, 256–263.
Chen, J., Smaoui, N., Hammer, M.B., Jiao, X., Riazuddin, S.A., Harper, S., Katsanis,
N.,  Riazuddin, S., Chaabouni, H., Berson, E.L., Hejtmancik, J.F., 2011. Molecular
analysis of Bardet-Biedl syndrome families: report of 21 novel mutations in 10
genes. Invest. Ophthalmol. Vis. Sci. 52, 5317–5324.
Chen, L.Y., Rex, C.S., Babayan, A.H., Kramar, E.A., Lynch, G., Gall, C.M., Lauterborn,
J.C., 2010. Physiological activation of synaptic Rac > PAK (p-21 activated kinase)
signaling is defective in a mouse model of fragile X syndrome. J. Neurosci. 30,
10977–10984.
Chilian, B., Abdollahpour, H., Bierhals, T., Haltrich, I., Fekete, G., Nagel, I., Rosenberger,
G.,  Kutsche, K., 2013. Dysfunction of SHANK2 and CHRNA7 in a patient with
intellectual disability and language impairment supports genetic epistasis of
the  two loci. Clin. Genet.
Choi, C.H., Schoenfeld, B.P., Bell, A.J., Hinchey, P., Kollaros, M.,  Gertner, M.J., Woo, N.H.,
Tranfaglia, M.R., Bear, M.F., Zukin, R.S., McDonald, T.V., Jongens, T.A., McBride,
S.M.J., 2011. Pharmacological reversal of synaptic plasticity deﬁcits in the mouse
model of fragile X syndrome by group II mGluR antagonist or lithium treatment.
Brain Res. 1380, 106–119.
Coffee, R.L., Williamson, A.J., Adkins, C.M., Gray, M.C., Page, T.L., Broadie, K., 2012.
In vivo neuronal function of the fragile X mental retardation protein is regulated
by  phosphorylation. Hum. Mol. Genet. 21, 900–915.
Connolly, J.B., Roberts, I.J., Armstrong, J.D., Kaiser, K., Forte, M.,  Tully, T., O’Kane,
C.J.,  1996. Associative learning disrupted by impaired Gs signaling in Drosophila
mushroom bodies. Science 274, 2104–2107.
Psychiatric Genomics Consortium, Cross-Disorder Group of the Psychiatric
Genomics Consortium, Genetic Risk Outcome of Psychosis (GROUP) Consortium,
2013. Identiﬁcation of risk loci with shared effects on ﬁve major psychiatric
disorders: a genome-wide analysis. Lancet 381, 1371–1379.
Contractor, A., 2013. Broadening roles for FMRP: big news for big potassium (BK)
channels. Neuron 77, 601–603.
Cukier, H.N., Perez, A.M., Collins, A.L., Zhou, Z., Zoghbi, H.Y., Botas, J., 2008. Genetic
modiﬁers of MeCP2 function in Drosophila. PLoS Genet. 4, e1000179.
Curatolo, P., Paloscia, C., D’Agati, E., Moavero, R., Pasini, A., 2009. The neurobiology
of  attention deﬁcit/hyperactivity disorder. Eur. J. Paediat. Neurol. 13, 299–304.
Cvetkovska, V., Hibbert, A.D., Emran, F., Chen, B.E., 2013. Overexpression of Down
syndrome cell adhesion molecule impairs precise synaptic targeting. Nat. Neu-
rosci. 16, 677–682.
D’Hulst, C., De Geest, N., Reeve, S.P., Van Dam, D., De Deyn, P.P., Hassan, B.A., Kooy,
R.F., 2006. Decreased expression of the GABAA receptor in fragile X syndrome.
Brain Res. 22, 238–245.
Dankert, H., Wang, L., Hoopfer, E.D., Anderson, D.J., Perona, P., 2009. Automated mon-
itoring and analysis of social behavior in Drosophila. Nat. Methods 6, 297–303.
Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F.,
Chen, C., Fak, J.J., Chi, S.W., Licatalosi, D.D., Richter, J.D., Darnell, R.B., 2011. FMRP
stalls ribosomal translocation on mRNAs linked to synaptic function and autism.
Cell  146, 247–261.
Davis, R.L., 2011. Traces of Drosophila memory. Neuron 70, 8–19.
de Ligt, J., Willemsen, M.H., van Bon, B.W.M., Kleefstra, T., Yntema, H.G., Kroes, T.,
Vulto-van Silfhout, A.T., Koolen, D.A., de Vries, P., Gilissen, C., del Rosario, M.,
Hoischen, A., Scheffer, H., de Vries, B.B.A., Brunner, H.G., Veltman, J.A., Vissers,
L.E.L.M., 2012. Diagnostic exome sequencing in persons with severe intellectual
disability. N. Engl. J. Med. 367, 1921–1929.
de Vrij, F.M., Levenga, J., van der Linde, H.C., Koekkoek, S.K., De Zeeuw, C.I., Nel-
son,  D.L., Oostra, B.A., Willemsen, R., 2008. Rescue of behavioral phenotype and
neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 31, 127–132.
Devuyst, O., Christie, P.T., Courtoy, P.J., Beauwens, R., Thakker, R.V., 1999. Intra-renal
and  subcellular distribution of the human chloride channel, CLC-5, reveals a
pathophysiological basis for Dent’s disease. Hum. Mol. Genet. 8, 247–257.
Didelot, G., Molinari, F., Tchenio, P., Comas, D., Milhiet, E., Munnich, A., Colleaux, L.,
Preat, T., 2006. Tequila, a neurotrypsin ortholog, regulates long-term memory
formation in Drosophila. Science 313, 851–853.
Dierssen, M.,  Ramakers, G.J., 2006. Dendritic pathology in mental retardation: from
molecular genetics to neurobiology. Genes Brain Behav. 5 (Suppl. 2), 48–60.
Dietzl, G., Chen, D., Schnorrer, F., Su, K.C., Barinova, Y., Fellner, M.,  Gasser, B., Kin-
sey, K., Oppel, S., Scheiblauer, S., Couto, A., Marra, V., Keleman, K., Dickson, B.J.,
2007. A genome-wide transgenic RNAi library for conditional gene inactivation
in  Drosophila. Nature 448, 151–156.
Dockendorff, T.C., Su, H.S., McBride, S.M., Yang, Z., Choi, C.H., Siwicki, K.K., Sehgal, A.,
Jongens, T.A., 2002. Drosophila lacking dfmr1 activity show defects in circadian
output and fail to maintain courtship interest. Neuron 34, 973–984.
Dubnau, J., Chiang, A.S., Grady, L., Barditch, J., Gossweiler, S., McNeil, J., Smith, P.,
Buldoc, F., Scott, R., Certa, U., Broger, C., Tully, T., 2003. The staufen/pumilio
pathway is involved in Drosophila long-term memory. Curr. Biol. 13, 286–296.
Dubnau, J., Tully, T., 1998. Gene discovery in Drosophila: new insights for learning
and memory. Ann. Rev. Neurosci. 21, 407–444.
Duffy, J.B., 2002. GAL4 system in Drosophila: a ﬂy geneticist’s Swiss army knife.
Genesis 34, 1–15.
Ehninger, D., Li, W.,  Fox, K., Stryker, M.P., Silva, A.J., 2008. Reversing neurodevelop-
mental disorders in adults. Neuron 60, 950–960.
El Idrissi, A., Ding, X.H., Scalia, J., Trenkner, E., Brown, W.T., Dobkin, C., 2005.
Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse.
Neurosci. Lett. 377, 141–146.
Elia, J., Sackett, J., Turner, T., Schardt, M.,  Tang, S.-C., Kurtz, N., Dunfey, M., McFarlane,
N.A., Susi, A., Danish, D., Li, A., Nissley-Tsiopinis, J., Borgmann-Winter, K., 2012.
Attention-deﬁcit/hyperactivity disorder genomics: update for clinicians. Curr.
Psychiatry Rep. 14, 579–589.
Ellison, J.W., Rosenfeld, J.A., Shaffer, L.G., 2013. Genetic basis of intellectual disability.
Annu. Rev. Med. 64, 441–450.
ENCORE, ENCORE Expertisecentrum voor Erfelijke NeuroCognitieve Ontwikkel-
ingsstoornissen. Rotterdam Erasmus MC.
Engel, J.E., Wu,  C.-F., 2009. Neurogenetic approaches to habituation and dishabitu-
ation in Drosophila.  Neurobiol. Learn. Mem. 92, 166–175.
Erdmann, K.S., Mao, Y., McCrea, H.J., Zoncu, R., Lee, S., Paradise, S., Modregger, J.,
Biemesderfer, D., Toomre, D., De Camilli, P., 2007. A role of the Lowe syndrome
protein OCRL in early steps of the endocytic pathway. Develop. Cell 13, 377–390.
340 M. van der Voet et al. / Neuroscience and Biobehavioral Reviews 46 (2014) 326–342
Fahrner, J.A., Frazier, A., Bachir, S., Walsh, M.F., Applegate, C.D., Thompson, R.,
Halushka, M.K., Murphy, A.M., Gunay-Aygun, M.,  2012. A rasopathy phenotype
with severe congenital hypertrophic obstructive cardiomyopathy associated
with a PTPN11 mutation and a novel variant in SOS1. Am.  J. Med. Genet. A 158A,
1414–1421.
Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A.,
Sklar, P., 2005. Molecular genetics of attention-deﬁcit/hyperactivity disorder.
BPS 57, 1313–1323.
Fauser, S., Munz, M.,  Besch, D., 2003. Further support for digenic inheritance in
Bardet-Biedl syndrome. J. Med. Genet. 40, e104.
Fischbach, K.-F., Heisenberg, M., 1984. Neurogenetics and behaviour in insects. J.
Exp. Biol. 112, 65–93.
Flicek, P., Ahmed, I., Amode, M.R., Barrell, D., Beal, K., Brent, S., Carvalho-Silva, D.,
Clapham, P., Coates, G., Fairley, S., Fitzgerald, S., Gil, L., Garcia-Giron, C., Gordon,
L., Hourlier, T., Hunt, S., Juettemann, T., Kahari, A.K., Keenan, S., Komorowska, M.,
Kulesha, E., Longden, I., Maurel, T., McLaren, W.M.,  Muffato, M., Nag, R., Overduin,
B., Pignatelli, M.,  Pritchard, B., Pritchard, E., Riat, H.S., Ritchie, G.R., Rufﬁer, M.,
Schuster, M.,  Sheppard, D., Sobral, D., Taylor, K., Thormann, A., Trevanion, S.,
White, S., Wilder, S.P., Aken, B.L., Birney, E., Cunningham, F., Dunham, I., Harrow,
J.,  Herrero, J., Hubbard, T.J., Johnson, N., Kinsella, R., Parker, A., Spudich, G., Yates,
A., Zadissa, A., Searle, S.M., 2013. Ensembl 2013. Nucleic Acids Res. 41, D48–D55.
Forrest, M.,  Chapman, R.M., Doyle, A.M., Tinsley, C.L., Waite, A., Blake, D.J., 2012. Func-
tional analysis of TCF4 missense mutations that cause Pitt-Hopkins syndrome.
Hum. Mutat. 33, 1676–1686.
Fradkin, L.G., Baines, R.A., van der Plas, M.C., Noordermeer, J.N., 2008. The dys-
trophin Dp186 isoform regulates neurotransmitter release at a central synapse
in  Drosophila. J. Neurosci. 28, 5105–5114.
Godenschwege, T.A., Kristiansen, L.V., Uthaman, S.B., Hortsch, M., Murphey, R.K.,
2006. A conserved role for Drosophila Neuroglian and human L1-CAM in central-
synapse formation. Curr. Biol. 16, 12–23.
Gonzaga-Jauregui, C., Lupski, J.R., Gibbs, R.A., 2012. Human genome sequencing in
health and disease. Annu. Rev. Med. 63, 35–61.
Guo, H.F., Tong, J., Hannan, F., Luo, L., Zhong, Y., 2000. A neuroﬁbromatosis-1-
regulated pathway is required for learning in Drosophila. Nature 403, 895–898.
Haddad, D.M., Vilain, S., Vos, M.,  Esposito, G., Matta, S., Kalscheuer, V.M., Craessaerts,
K.,  Leyssen, M.,  Nascimento, R.M.P., Vianna-Morgante, A.M., De Strooper, B., Van
Esch, H., Morais, V.A., Verstreken, P., 2013. Mutations in the intellectual dis-
ability gene Ube2a cause neuronal dysfunction and impair Parkin-dependent
mitophagy. Mol. Cell 50, 831–843.
Hahn, N., Geurten, B., Gurvich, A., Piepenbrock, D., Kästner, A., Zanini, D., Xing, G.,
Xie, W.,  Göpfert, M.C., Ehrenreich, H., Heinrich, R., 2013. Monogenic heritable
autism gene neuroligin impacts Drosophila social behaviour. Behav. Brain Res.
252, 450–457.
Hamshere, M.L., Stergiakouli, E., Langley, K., Martin, J., Holmans, P., Kent, L., Owen,
M.J., Gill, M.,  Thapar, A., O’Donovan, M.,  Craddock, N., 2013. Shared polygenic
contribution between childhood attention-deﬁcit hyperactivity disorder and
adult schizophrenia. Br. J. Psychiatry 203, 107–111.
Harbison, S.T., MACKAY, T.F.C., Anholt, R.R.H., 2009. Understanding the neurogenet-
ics  of sleep: progress from Drosophila. Trends Genet. TIG 25, 262–269.
Hashimoto, S., Boissel, S., Zarhrate, M.,  Rio, M.,  Munnich, A., Egly, J.-M., Colleaux, L.,
2011. MED23 mutation links intellectual disability to dysregulation of immedi-
ate early gene expression. Science 333, 1161–1163.
Hattori, D., Millard, S.S., Wojtowicz, W.M.,  Zipursky, S.L., 2008. Dscam-mediated
cell recognition regulates neural circuit formation. Annu. Rev. Cell Dev. Biol. 24,
597–620.
Hehir-Kwa, J.Y., Wieskamp, N., Webber, C., Pfundt, R., Brunner, H.G., Gilissen, C., de
Vries, B.B., Ponting, C.P., Veltman, J.A., 2010. Accurate distinction of pathogenic
from benign CNVs in mental retardation. PLoS Comput. Biol. 6, e1000752.
Heulens, I., D’Hulst, C., Van Dam, D., De Deyn, P.P., Kooy, R.F., 2012. Pharmacological
treatment of fragile X syndrome with GABAergic drugs in a knockout mouse
model. Behav. Brain Res. 229, 244–249.
Hjortshøj, T.D., Grønskov, K., Philp, A.R., Nishimura, D.Y., Riise, R., Shefﬁeld, V.C.,
Rosenberg, T., Brøndum-Nielsen, K., 2010. Bardet-Biedl syndrome in Denmark –
report of 13 novel sequence variations in six genes. Hum. Mutat. 31, 429–436.
Hoischen, A., van Bon, B.W., Gilissen, C., Arts, P., van Lier, B., Steehouwer, M., de Vries,
P., de Reuver, R., Wieskamp, N., Mortier, G., Devriendt, K., Amorim, M.Z., Revencu,
N.,  Kidd, A., Barbosa, M.,  Turner, A., Smith, J., Oley, C., Henderson, A., Hayes,
I.M., Thompson, E.M., Brunner, H.G., de Vries, B.B., Veltman, J.A., 2010. De novo
mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat. Genet. 42, 483–485.
Honda, S., Satomura, S., Hayashi, S., Imoto, I., Nakagawa, E., Goto Y., Inazawa, J.,
Japanese Mental Retardation Consortium, 2012. Concomitant microduplications
of  MECP2 and ATRX in male patients with severe mental retardation. J. Hum.
Genet. 57, 73–77.
Hortsch, M.,  Nagaraj, K., Godenschwege, T.A., 2009. The interaction between L1-type
proteins and ankyrins – a master switch for L1-type CAM function. Cell. Mol. Biol.
Lett. 14, 57–69.
Hoyer, J., Ekici, A.B., Endele, S., Popp, B., Zweier, C., Wiesener, A., Wohlleber, E., Dufke,
A., Rossier, E., Petsch, C., Zweier, M.,  Gohring, I., Zink, A.M., Rappold, G., Schrock,
E.,  Wieczorek, D., Riess, O., Engels, H., Rauch, A., Reis, A., 2012. Haploinsufﬁciency
of  ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a
frequent cause of intellectual disability. Am.  J. Hum. Genet. 90, 565–572.
Huang, H., Vasung, L., 2013. Gaining insight of fetal brain development with diffusion
MRI  and histology. Int. J. Dev. Neurosci. 21, 00102–00100.
Inoue, S., Shimoda, M.,  Nishinokubi, I., Siomi, M.,  Okamura, M., Nakamura, A.,
Kobayashi, S., Ishida, N., Siomi, H., 2002. A role for the Drosophila fragile x-related
gene in circadian output. Curr. Biol. 12, 1331.
Iqbal, Z., Vandeweyer, G., van der Voet, M.,  Waryah, A.M., Zahoor, M.Y., Besseling,
J.A.,  Roca, L.T., Vulto-van Silfhout, A.T., Nijhof, B., Kramer, J.M., Van der Aa, N.,
Ansar, M.,  Peeters, H., Helsmoortel, C., Gilissen, C., Vissers, L.E.L.M., Veltman, J.A.,
de  Brouwer, A.P.M., Frank Kooy, R., Riazuddin, S., Schenck, A., van Bokhoven, H.,
Rooms, L., 2013. Homozygous and heterozygous disruptions of ANK3: at the
crossroads of neurodevelopmental and psychiatric disorders. Hum. Mol. Genet.
22, 1960–1970.
Ishizuka, A., Siomi, M.C., Siomi, H., 2002. A Drosophila fragile X protein interacts with
components of RNAi and ribosomal proteins. Genes Develop. 16, 2497–2508.
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M.G., Berry-Kravis, E., Hagerman,
R.J., Ramos, F.J., Cornish, K., He, Y., Paulding, C., Neri, G., Chen, F., Hadjikhani, N.,
Martinet, D., Meyer, J., Beckmann, J.S., Delange, K., Brun, A., Bussy, G., Gasparini,
F.,  Hilse, T., Floesser, A., Branson, J., Bilbe, G., Johns, D., Gomez-Mancilla, B., 2011.
Epigenetic modiﬁcation of the FMR1 gene in fragile X syndrome is associated
with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med.
3,  3001708.
Jan, Y.-N., Jan, L.Y., 2010. Branching out: mechanisms of dendritic arborization. Nat.
Pub.  Group 11, 316–328.
Jensen, L., Farook, M.F., Reiter, L.T., 2013. Proteomic proﬁling in Drosophila reveals
potential Dube3a regulation of the actin cytoskeleton and neuronal homeostasis.
PLoS One 8, e61952.
Jin, P., Zarnescu, D.C., Ceman, S., Nakamoto, M.,  Mowrey, J., Jongens, T.A., Nelson, D.L.,
Moses, K., Warren, S.T., 2004. Biochemical and genetic interaction between the
fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci.
7,  113–117.
Jin, S., Pan, L., Liu, Z., Wang, Q., Xu, Z., Zhang, Y.Q., 2009. Drosophila tubulin-speciﬁc
chaperone E functions at neuromuscular synapses and is required for micro-
tubule network formation. Development 136, 1571–1581.
Karim, F.D., Chang, H.C., Therrien, M.,  Wassarman, D.A., Laverty, T., Rubin, G.M.,
1996. A screen for genes that function downstream of Ras1 during Drosophila
eye development. Genetics 143, 315–329.
Katsanis, N., Ansley, S.J., Badano, J.L., Eichers, E.R., Lewis, R.A., Hoskins, B.E., Scambler,
P.J.,  Davidson, W.S., Beales, P.L., Lupski, J.R., 2001. Triallelic inheritance in Bardet-
Biedl syndrome, a Mendelian recessive disorder. Science 293, 2256–2259.
Katsanis, N., Eichers, E.R., Ansley, S.J., Lewis, R.A., Kayserili, H., Hoskins, B.E., Scambler,
P.J., Beales, P.L., Lupski, J.R., 2002. BBS4 is a minor contributor to Bardet-Biedl
syndrome and may  also participate in triallelic inheritance. Am.  J. Hum. Genet.
71, 22–29.
Kaufmann, W.E., Moser, H.W., 2000. Dendritic anomalies in disorders associated
with mental retardation. Cereb. Cortex 10, 981–991.
Kim, J.H., Wang, X., Coolon, R., Ye, B., 2013a. Dscam expression levels determine
presynaptic arbor sizes in Drosophila sensory neurons. Neuron 78, 827–838.
Kim, S., Chahrour, M.,  Ben-Shachar, S., Lim, J., 2013b. Ube3a/E6AP is involved in a
subset of MeCP2 functions. Biochem. Biophys. Res. Commun. 437, 67–73.
Kleefstra, T., Brunner, H.G., Amiel, J., Oudakker, A.R., Nillesen, W.M.,  Magee, A.,
Genevieve, D., Cormier-Daire, V., van Esch, H., Fryns, J.P., Hamel, B.C., Sister-
mans, E.A., de Vries, B.B., van Bokhoven, H., 2006. Loss-of-function mutations in
euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelom-
eric deletion syndrome. Am. J. Hum. Genet. 79, 370–377.
Kleefstra, T., Kramer, J.M., Neveling, K., Willemsen, M.H., Koemans, T.S., Vissers,
L.E.L.M., Wissink-Lindhout, W.,  Fenckova, M.,  van den Akker, W.M.R., Kasri,
N.N., Nillesen, W.M.,  Prescott, T., Clark, R.D., Devriendt, K., van Reeuwijk, J., de
Brouwer, A.P.M., Gilissen, C., Zhou, H., Brunner, H.G., Veltman, J.A., Schenck,
A., van Bokhoven, H., 2012. Disruption of an EHMT1-associated chromatin-
modiﬁcation module causes intellectual disability. Am. J. Hum. Genet. 91,
73–82.
Kleefstra, T., van Zelst-Stams, W.A., Nillesen, W.M.,  Cormier-Daire, V., Houge, G.,
Foulds, N., van Dooren, M.,  Willemsen, M.H., Pfundt, R., Turner, A., Wilson, M.,
McGaughran, J., Rauch, A., Zenker, M.,  Adam, M.P., Innes, M., Davies, C., López,
A.G.-M., Casalone, R., Weber, A., Brueton, L.A., Navarro, A.D., Bralo, M.P., Vense-
laar, H., Stegmann, S.P.A., Yntema, H.G., van Bokhoven, H., Brunner, H.G., 2009.
Further clinical and molecular delineation of the 9q subtelomeric deletion syn-
drome supports a major contribution of EHMT1 haploinsufﬁciency to the core
phenotype. J. Med. Genet. 46, 598–606.
Koch, I., Schwarz, H., Beuchle, D., Goellner, B., Langegger, M., Aberle, H.,
2008. Drosophila ankyrin 2 is required for synaptic stability. Neuron 58,
210–222.
Koolen, D.A., Kramer, J.M., Neveling, K., Nillesen, W.M.,  Moore-Barton, H.L., Elm-
slie, F.V., Toutain, A., Amiel, J., Malan, V., Tsai, A.C.-H., Cheung, S.W., Gilissen, C.,
Verwiel, E.T.P., Martens, S., Feuth, T., Bongers, E.M.H.F., de Vries, P., Scheffer, H.,
Vissers, L.E.L.M., de Brouwer, A.P.M., Brunner, H.G., Veltman, J.A., Schenck, A.,
Yntema, H.G., de Vries, B.B.A., 2012. Mutations in the chromatin modiﬁer gene
KANSL1 cause the 17q21.31 microdeletion syndrome. Nat. Genet. 44, 639–641.
Krab, L.C., de Goede-Bolder, A., Aarsen, F.K., Pluijm, S.M., Bouman, M.J., van der Geest,
J.N., Lequin, M.,  Catsman, C.E., Arts, W.F., Kushner, S.A., Silva, A.J., de Zeeuw, C.I.,
Moll, H.A., Elgersma, Y., 2008a. Effect of simvastatin on cognitive functioning in
children with neuroﬁbromatosis type 1: a randomized controlled trial. J. Am.
Med. Assoc. 300, 287–294.
Krab, L.C., Goorden, S.M., Elgersma, Y., 2008b. Oncogenes on my mind: ERK and
MTOR signaling in cognitive diseases. Trends Genet. 24, 498–510.
Kramer, J.M., Kochinke, K., Oortveld, M.A., Marks, H., Kramer, D., de Jong, E.K., Aszta-
los, Z., Westwood, J.T., Stunnenberg, H.G., Sokolowski, M.B., Keleman, K., Zhou,
H.,  van Bokhoven, H., Schenck, A., 2011. Epigenetic regulation of learning and
memory by Drosophila EHMT/G9a. PLoS Biol. 9, e1000569.
Kramer, J.M., van Bokhoven, H., 2009. Genetic and epigenetic defects in mental
retardation. Int. J. Biochem. Cell Biol. 41, 96–107.
M. van der Voet et al. / Neuroscience and Biobehavioral Reviews 46 (2014) 326–342 341
Kriaucionis, S., Paterson, A., Curtis, J., Guy, J., Macleod, N., Bird, A., 2006. Gene expres-
sion analysis exposes mitochondrial abnormalities in a mouse model of Rett
syndrome. Mol. Cell. Biol. 26, 5033–5042.
Ku, C.S., Polychronakos, C., Tan, E.K., Naidoo, N., Pawitan, Y., Roukos, D.H., Mort,
M.,  Cooper, D.N., 2013. A new paradigm emerges from the study of de novo
mutations in the context of neurodevelopmental disease. Mol. Psychiatry 18,
141–153.
Lamprecht, R., LeDoux, J., 2004. Structural plasticity and memory. Nature reviews.
Neuroscience 5, 45–54.
Leblond, C.S., Heinrich, J., Delorme, R., Proepper, C., Betancur, C., Huguet, G., Konyukh,
M., Chaste, P., Ey, E., Rastam, M.,  Anckarsäter, H., Nygren, G., Gillberg, I.C., Melke,
J.,  Toro, R., Regnault, B., Fauchereau, F., Mercati, O., Lemière, N., Skuse, D., Poot,
M.,  Holt, R., Monaco, A.P., Järvelä, I., Kantojärvi, K., Vanhala, R., Curran, S., Collier,
D.A., Bolton, P., Chiocchetti, A., Klauck, S.M., Poustka, F., Freitag, C.M., Waltes, R.,
Kopp, M.,  Duketis, E., Bacchelli, E., Minopoli, F., Ruta, L., Battaglia, A., Mazzone, L.,
Maestrini, E., Sequeira, A.F., Oliveira, B., Vicente, A., Oliveira, G., Pinto, D., Scherer,
S.W., Zelenika, D., Delepine, M.,  Lathrop, M.,  Bonneau, D., Guinchat, V., Devillard,
F., Assouline, B., Mouren, M.-C., Leboyer, M.,  Gillberg, C., Boeckers, T.M., Bourg-
eron, T., 2012. Genetic and functional analyses of SHANK2 mutations suggest a
multiple hit model of autism spectrum disorders. PLoS Genet. 8, e1002521.
Lee, A., Li, W.,  Xu, K., Bogert, B.A., Su, K., Gao, F.B., 2003. Control of dendritic develop-
ment by the Drosophila fragile X-related gene involves the small GTPase Rac1.
Development 130, 5543–5552.
Lee, N.G., Hong, Y.K., Yu, S.Y., Han, S.Y., Geum, D., Cho, K.S., 2007. dXNP, a Drosophila
homolog of XNP/ATRX, induces apoptosis via Jun-N-terminal kinase activation.
FEBS Lett. 581, 2625–2632.
Li, W.,  Cui, Y., Kushner, S.A., Brown, R.A., Jentsch, J.D., Frankland, P.W., Cannon, T.D.,
Silva, A.J., 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learn-
ing and attention deﬁcits in a mouse model of neuroﬁbromatosis type 1. Curr.
Biol. 15, 1961–1967.
Lonze, B.E., Ginty, D.D., 2002. Function and regulation of CREB family transcription
factors in the nervous system. Neuron 35, 605–623.
Lu, Y., Wang, F., Li, Y., Ferris, J., Lee, J.A., Gao, F.B., 2009. The Drosophila homologue
of  the Angelman syndrome ubiquitin ligase regulates the formation of terminal
dendritic branches. Hum. Mol. Genet. 18, 454–462.
Maimon, G., Straw, A.D., Dickinson, M.H., 2008. A simple vision-based algorithm for
decision making in ﬂying Drosophila. Curr. Biol. 18, 464–470.
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J.,
McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., Cho, J.H., Guttmacher,
A.E., Kong, A., Kruglyak, L., Mardis, E., Rotimi, C.N., Slatkin, M.,  Valle, D., Whitte-
more, A.S., Boehnke, M.,  Clark, A.G., Eichler, E.E., Gibson, G., Haines, J.L., Mackay,
T.F.C., McCarroll, S.A., Visscher, P.M., 2009. Finding the missing heritability of
complex diseases. Nature 461, 747–753.
Marrone, A.K., Kucherenko, M.M.,  Rishko, V.M., Shcherbata, H.R., 2011. New dys-
trophin/dystroglycan interactors control neuron behavior in Drosophila eye.
BMC  Neurosci. 12, 93.
Marygold, S.J., Leyland, P.C., Seal, R.L., Goodman, J.L., Thurmond, J., Strelets, V.B.,
Wilson, R.J., FlyBase, c., 2013. FlyBase: improvements to the bibliography. Nucl.
Acids Res. 41, D751–D757.
Matthews, K.A., Kaufman, T.C., Gelbart, W.M.,  2005. Research resources for
Drosophila:  the expanding universe. Nat. Rev. Genet. 6, 179–193.
McBride, S.M., Choi, C.H., Wang, Y., Liebelt, D., Braunstein, E., Ferreiro, D., Sehgal, A.,
Siwicki, K.K., Dockendorff, T.C., Nguyen, H.T., McDonald, T.V., Jongens, T.A., 2005.
Pharmacological rescue of synaptic plasticity, courtship behavior, and mush-
room body defects in a Drosophila model of fragile X syndrome. Neuron 45,
753–764.
Mefford, H.C., Batshaw, M.L., Hoffman, E.P., 2012. Genomics, intellectual disability,
and autism. N. Engl. J. Med. 366, 733–743.
Menet, J.S., Rosbash, M.,  2011. When brain clocks lose track of time: cause or conse-
quence of neuropsychiatric disorders. Curr. Opin. Neurobiol. 21, 849–857.
Miao, S., Chen, R., Ye, J., Tan, G.H., Li, S., Zhang, J., Jiang, Y.H., Xiong, Z.Q., 2013. The
Angelman syndrome protein Ube3a is required for polarized dendrite morpho-
genesis in pyramidal neurons. J. Neurosci. 33, 327–333.
Michel, C.I., Kraft, R., Restifo, L.L., 2004. Defective neuronal development in the mush-
room  bodies of Drosophila fragile X mental retardation 1 mutants. J. Neurosci.
24, 5798–5809.
Ming, J.E., Muenke, M., 2002. Multiple hits during early embryonic development:
digenic diseases and holoprosencephaly. Am.  J. Hum. Genet. 71, 1017–1032.
Møller, R.S., Kübart, S., Hoeltzenbein, M.,  Heye, B., Vogel, I., Hansen, C.P., Menzel,
C.,  Ullmann, R., Tommerup, N., Ropers, H.-H., Tümer, Z., Kalscheuer, V.M., 2008.
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated
patients with microcephaly. Am.  J. Hum. Genet. 82, 1165–1170.
Morales, J., Hiesinger, P.R., Schroeder, A.J., Kume, K., Verstreken, P., Jackson, F.R.,
Nelson, D.L., Hassan, B.A., 2002. Drosophila fragile X protein, DFXR, regulates
neuronal morphology and function in the brain. Neuron 34, 961–972.
Morris, S.E., Cuthbert, B.N., 2012. Research domain criteria: cognitive systems, neural
circuits, and dimensions of behavior. Dialog. Clin. Neurosci. 14, 29–37.
Mouri, K., Horiuchi, S.Y., Uemura, T., 2012. Cohesin controls planar cell polarity by
regulating the level of the seven-pass transmembrane cadherin Flamingo. Genes
Cells 17, 509–524.
Mukhopadhyay, A., Kramer, J.M., Merkx, G., Lugtenberg, D., Smeets, D.F., Oortveld,
M.A., Blokland, E.A., Agrawal, J., Schenck, A., van Bokhoven, H., Huys, E., Schoen-
makers, E.F., van Kessel, A.G., van Nouhuys, C.E., Cremers, F.P., 2010. CDK19
is  disrupted in a female patient with bilateral congenital retinal folds, micro-
cephaly and mild mental retardation. Hum. Genet. 128, 281–291.
Nadif Kasri, N., Van Aelst, L., 2008. Rho-linked genes and neurological disorders.
Pﬂugers Arch. 455, 787–797.
Najmabadi, H., Hu, H., Garshasbi, M.,  Zemojtel, T., Abedini, S.S., Chen, W.,  Hosseini,
M.,  Behjati, F., Haas, S., Jamali, P., Zecha, A., Mohseni, M.,  Puttmann, L., Vahid, L.N.,
Jensen, C., Moheb, L.A., Bienek, M.,  Larti, F., Mueller, I., Weissmann, R., Darvish,
H.,  Wrogemann, K., Hadavi, V., Lipkowitz, B., Esmaeeli-Nieh, S., Wieczorek, D.,
Kariminejad, R., Firouzabadi, S.G., Cohen, M.,  Fattahi, Z., Rost, I., Mojahedi, F.,
Hertzberg, C., Dehghan, A., Rajab, A., Banavandi, M.J.S., Hoffer, J., Falah, M.,
Musante, L., Kalscheuer, V., Ullmann, R., Kuss, A.W., Tzschach, A., Kahrizi, K., Rop-
ers, H.H., 2011. Deep sequencing reveals 50 novel genes for recessive cognitive
disorders. Nature 478, 57–63.
Nan, X., Hou, J., Maclean, A., Nasir, J., Lafuente, M.J., Shu, X., Kriaucionis, S., Bird, A.,
2007. Interaction between chromatin proteins MECP2 and ATRX is disrupted by
mutations that cause inherited mental retardation. Proc. Natl. Acad. Sci. U. S. A.
104, 2709–2714.
Nanni, L., Ming, J.E., Bocian, M.,  Steinhaus, K., Bianchi, D.W., Die-Smulders, C., Gian-
notti, A., Imaizumi, K., Jones, K.L., Campo, M.D., Martin, R.A., Meinecke, P.,
Pierpont, M.E., Robin, N.H., Young, I.D., Roessler, E., Muenke, M., 1999. The
mutational spectrum of the sonic hedgehog gene in holoprosencephaly: SHH
mutations cause a signiﬁcant proportion of autosomal dominant holoprosen-
cephaly. Hum. Mol. Genet. 8, 2479–2488.
Ng, S.B., Bigham, A.W., Buckingham, K.J., Hannibal, M.C., McMillin, M.J., Gildersleeve,
H.I., Beck, A.E., Tabor, H.K., Cooper, G.M., Mefford, H.C., Lee, C., Turner, E.H.,
Smith, J.D., Rieder, M.J., Yoshiura, K., Matsumoto, N., Ohta, T., Niikawa, N., Nicker-
son,  D.A., Bamshad, M.J., Shendure, J., 2010a. Exome sequencing identiﬁes MLL2
mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790–793.
Ng, S.B., Nickerson, D.A., Bamshad, M.J., Shendure, J., 2010b. Massively parallel
sequencing and rare disease. Hum. Mol. Genet. 19, R119–R124.
O’Roak, B.J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J.J., Girirajan, S., Karakoc, E.,
Mackenzie, A.P., Ng, S.B., Baker, C., Rieder, M.J., Nickerson, D.A., Bernier, R., Fisher,
S.E., Shendure, J., Eichler, E.E., 2011. Exome sequencing in sporadic autism spec-
trum disorders identiﬁes severe de novo mutations. Nat. Genet. 43, 585–589.
O’Roak, B.J., Vives, L., Girirajan, S., Karakoc, E., Krumm, N., Coe, B.P., Levy, R., Ko, A., Lee,
C.,  Smith, J.D., Turner, E.H., Stanaway, I.B., Vernot, B., Malig, M.,  Baker, C., Reilly,
B.,  Akey, J.M., Borenstein, E., Rieder, M.J., Nickerson, D.A., Bernier, R., Shendure,
J.,  Eichler, E.E., 2012. Sporadic autism exomes reveal a highly interconnected
protein network of de novo mutations. Nature 485, 246–250.
Ojelade, S.A., Rothenﬂuh, A., 2009. Addiction: ﬂies hit the skids. Curr. Biol. 19,
R1110–R1111.
Oortveld, M.A.W., Keerthikumar, S., Oti, M.,  Nijhof, B., Fernandes, A.C., Kochinke,
K., Castells-Nobau, A., van Engelen, E., Ellenkamp, T., Eshuis, L., Galy, A., van
Bokhoven, H., Habermann, B., Brunner, H.G., Zweier, C., Verstreken, P., Huy-
nen, M.A., Schenck, A., 2013. Human intellectual disability genes from conserved
functional modules in Drosophila. PLoS Genet. 9, e1003911.
Oti, M.,  Brunner, H.G., 2007. The modular nature of genetic diseases. Clin. Genet. 71,
1–11.
Pak, C., Garshasbi, M.,  Kahrizi, K., Gross, C., Apponi, L.H., Noto, J.J., Kelly, S.M., Leung,
S.W., Tzschach, A., Behjati, F., Abedini, S.S., Mohseni, M., Jensen, L.R., Hu, H.,
Huang, B., Stahley, S.N., Liu, G., Williams, K.R., Burdick, S., Feng, Y., Sanyal, S.,
Bassell, G.J., Ropers, H.-H., Najmabadi, H., Corbett, A.H., Moberg, K.H., Kuss,
A.W., 2011. Mutation of the conserved polyadenosine RNA binding protein,
ZC3H14/dNab2, impairs neural function in Drosophila and humans. Proc. Natl.
Acad. Sci. U.S.A. 108, 12390–12395.
Pan, L., Zhang, Y.Q., Woodruff, E., Broadie, K., 2004. The Drosophila fragile X gene neg-
atively regulates neuronal elaboration and synaptic differentiation. Curr. Biol.
14, 1863–1870.
Pandey, U.B., Nichols, C.D., 2011. Human disease models in Drosophila melanogaster
and the role of the ﬂy in therapeutic drug discovery. Pharmacol. Rev. 63,
411–436.
Patel, A.B., Hays, S.A., Bureau, I., Huber, K.M., Gibson, J.R., 2013. A target cell-speciﬁc
role for presynaptic Fmr1 in regulating glutamate release onto neocortical fast-
spiking inhibitory neurons. J. Neurosci. 33, 2593–2604.
Pauli, A., Althoff, F., Oliveira, R.A., Heidmann, S., Schuldiner, O., Lehner, C.F., Dickson,
B.J., Nasmyth, K., 2008. Cell-type-speciﬁc TEV protease cleavage reveals cohesin
functions in Drosophila neurons. Develop. Cell 14, 13.
Pavlou, H.J., Goodwin, S.F., 2013. Courtship behavior in Drosophila melanogaster:
towards a ‘courtship connectome’. Curr. Opin. Neurobiol. 23, 76–83.
Pielage, J., Cheng, L., Fetter, R.D., Carlton, P.M., Sedat, J.W., Davis, G.W., 2008. A
presynaptic giant ankyrin stabilizes the NMJ through regulation of presynaptic
microtubules and transsynaptic cell adhesion. Neuron 58, 195–209.
Putz, G., Bertolucci, F., Raabe, T., Zars, T., Heisenberg, M.,  2004. The S6KII (rsk) gene of
Drosophila melanogaster differentially affects an operant and a classical learning
task. J. Neurosci. 24, 9745–9751.
Rachidi, M.,  Lopes, C., 2007. Mental retardation in Down syndrome: from gene
dosage imbalance to molecular and cellular mechanisms. Neurosci. Res. 59,
349–369.
Rauch, A., Wieczorek, D., Graf, E., Wieland, T., Endele, S., Schwarzmayr, T., Albrecht,
B.,  Bartholdi, D., Beygo, J., Di Donato, N., Dufke, A., Cremer, K., Hempel,
M.,  Horn, D., Hoyer, J., Joset, P., Röpke, A., Moog, U., Riess, A., Thiel, C.T.,
Tzschach, A., Wiesener, A., Wohlleber, E., Zweier, C., Ekici, A.B., Zink, A.M.,
Rump, A., Meisinger, C., Grallert, H., Sticht, H., Schenck, A., Engels, H., Rap-
pold, G., Schröck, E., Wieacker, P., Riess, O., Meitinger, T., Reis, A., Strom, T.M.,
2012. Range of genetic mutations associated with severe non-syndromic spo-
radic intellectual disability: an exome sequencing study. Lancet 380, 1674–
1682.
Reeve, S.P., Bassetto, L., Genova, G.K., Kleyner, Y., Leyssen, M.,  Jackson, F.R., Has-
san, B.A., 2005. The Drosophila fragile X mental retardation protein controls
actin dynamics by directly regulating proﬁlin in the brain. Curr. Biol. 15, 1156–
1163.
342 M. van der Voet et al. / Neuroscience and Biobehavioral Reviews 46 (2014) 326–342
Riviere, J.B., van Bon, B.W., Hoischen, A., Kholmanskikh, S.S., O’Roak, B.J., Gilissen, C.,
Gijsen, S., Sullivan, C.T., Christian, S.L., Abdul-Rahman, O.A., Atkin, J.F., Chassaing,
N., Drouin-Garraud, V., Fry, A.E., Fryns, J.P., Gripp, K.W., Kempers, M., Kleefstra, T.,
Mancini, G.M., Nowaczyk, M.J., van Ravenswaaij-Arts, C.M., Roscioli, T., Marble,
M.,  Rosenfeld, J.A., Siu, V.M., de Vries, B.B., Shendure, J., Verloes, A., Veltman, J.A.,
Brunner, H.G., Ross, M.E., Pilz, D.T., Dobyns, W.B., 2012. De novo mutations in
the actin genes ACTB and ACTG1 cause Baraitser-Winter syndrome. Nat. Genet.
44, 440–444.
Ropers, H.H., 2008. Genetics of intellectual disability. Curr. Opin. Genet. Dev. 18,
241–250.
Ropers, H.H., Hamel, B.C., 2005. X-linked mental retardation. Nat. Rev. Genet. 6,
46–57.
Ruiz-Canada, C., Budnik, V., 2006a. Introduction on the use of the Drosophila
embryonic/larval neuromuscular junction as a model system to study synapse
development and function, and a brief summary of pathﬁnding and target recog-
nition. Int. Rev. Neurobiol. 75, 1–31.
Ruiz-Canada, C., Budnik, V., 2006b. Synaptic cytoskeleton at the neuromuscular
junction. Int. Rev. Neurobiol. 75, 217–236.
Santen, G.W., Aten, E., Sun, Y., Almomani, R., Gilissen, C., Nielsen, M.,  Kant, S.G.,
Snoeck, I.N., Peeters, E.A., Hilhorst-Hofstee, Y., Wessels, M.W.,  den Hollander,
N.S., Ruivenkamp, C.A., van Ommen, G.J., Breuning, M.H., den Dunnen, J.T., van
Haeringen, A., Kriek, M.,  2012. Mutations in SWI/SNF chromatin remodeling
complex gene ARID1B cause Cofﬁn-Siris syndrome. Nat. Genet. 44, 379–380.
Sawamura, N., Ando, T., Maruyama, Y., Fujimuro, M.,  Mochizuki, H., Honjo, K., Shi-
moda, M.,  Toda, H., Sawamura-Yamamoto, T., Makuch, L.A., Hayashi, A., Ishizuka,
K.,  Cascella, N.G., Kamiya, A., Ishida, N., Tomoda, T., Hai, T., Furukubo-Tokunaga,
K.,  Sawa, A., 2008. Nuclear DISC1 regulates CRE-mediated gene transcription and
sleep  homeostasis in the fruit ﬂy. Mol. Psychiatry 13, 1138–1148, 1069.
Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.L., Giangrande, A., 2003.
CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1
GTPase pathway to the fragile X protein. Neuron 38, 887–898.
Schenck, A., Qurashi, A., Carrera, P., Bardoni, B., Diebold, C., Schejter, E., Mandel,
J.L., Giangrande, A., 2004. WAVE/SCAR, a multifunctional complex coordinating
different aspects of neuronal connectivity. Dev. Biol. 274, 260–270.
Schuldiner, O., Berdnik, D., Levy, J.M., Wu,  J.S., Luginbuhl, D., Gontang, A.C., Luo, L.,
2008. piggyBac-based mosaic screen identiﬁes a postmitotic function for cohesin
in regulating developmental axon pruning. Devlop. Cell 14, 12.
Schuurs-Hoeijmakers, J.H.M., Geraghty, M.T., Kamsteeg, E.-J., Ben-Salem, S., de Bot,
S.T., Nijhof, B., van de Vondervoort, I.I.G.M., van der Graaf, M.,  Nobau, A.C.,
Otte-Höller, I., Vermeer, S., Smith, A.C., Humphreys, P., Schwartzentruber, J.,
Consortium, F.C., Ali, B.R., Al-Yahyaee, S.A., Tariq, S., Pramathan, T., Bayoumi,
R., Kremer, H.P.H., van de Warrenburg, B.P., van den Akker, W.M.R., Gilissen,
C.,  Veltman, J.A., Janssen, I.M., Vulto-van Silfhout, A.T., van der Velde-Visser, S.,
Lefeber, D.J., Diekstra, A., Erasmus, C.E., Willemsen, M.A., Vissers, L.E.L.M., Lam-
mens, M.,  van Bokhoven, H., Brunner, H.G., Wevers, R.A., Schenck, A., Al-Gazali,
L.,  de Vries, B.B.A., de Brouwer, A.P.M., 2012. Mutations in DDHD2, encoding an
intracellular phospholipase A(1), cause a recessive form of complex hereditary
spastic paraplegia. Am.  J. Hum. Genet. 91, 1073–1081.
Shao, L., Shuai, Y., Wang, J., Feng, S., Lu, B., Li, Z., Zhao, Y., Wang, L., Zhong, Y.,
2011. Schizophrenia susceptibility gene dysbindin regulates glutamatergic and
dopaminergic functions via distinctive mechanisms in Drosophila. Proc. Natl.
Acad. Sci. U. S. A. 108, 18831–18836.
Sharma, P., Keane, J., O’Kane, C.J., Asztalos, Z., 2009. Automated measurement of
Drosophila jump reﬂex habituation and its use for mutant screening. J. Neurosci.
Methods 182, 43–48.
Skoulakis, E.M., Grammenoudi, S., 2006. Dunces and da Vincis: the genetics of learn-
ing and memory in Drosophila. Cell. Mol. Life Sci. 63, 975–988.
Sokolowski, M.B., 2010. Social interactions in simple model systems. Neuron 65,
780–794.
Sullivan, K., Hatton, D., Hammer, J., Sideris, J., Hooper, S., Ornstein, P., Bailey, D., 2006.
ADHD symptoms in children with FXS. Am.  J. Med. Genet. A 140, 2275–2288.
Tamura, T., Horiuchi, D., Chen, Y.C., Sone, M.,  Miyashita, T., Saitoe, M.,  Yoshimura,
N., Chiang, A.S., Okazawa, H., 2010. Drosophila PQBP1 regulates learning acqui-
sition at projection neurons in aversive olfactory conditioning. J. Neurosci. 30,
14091–14101.
Tessier, C.R., Broadie, K., 2008. Drosophila fragile X mental retardation protein
developmentally regulates activity-dependent axon pruning. Development 135,
1547–1557.
Therrien, M.,  Morrison, D.K., Wong, A.M., Rubin, G.M., 2000. A genetic screen for
modiﬁers of a kinase suppressor of Ras-dependent rough eye phenotype in
Drosophila.  Genetics 156, 1231–1242.
Thomas, G.M., Huganir, R.L., 2004. MAPK cascade signalling and synaptic plasticity.
Nat. Rev. Neurosci. 5, 173–183.
Tissir, F., Gofﬁnet, A.M., 2013. Shaping the nervous system: role of the core planar
cell  polarity genes. Nat. Rev. Neurosci. 14, 525–535.
Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y., Kaname, T.,
Naritomi, K., Kawame, H., Wakui, K., Fukushima, Y., Homma, T., Kato, M.,  Hiraki,
Y.,  Yamagata, T., Yano, S., Mizuno, S., Sakazume, S., Ishii, T., Nagai, T., Shiina, M.,
Ogata, K., Ohta, T., Niikawa, N., Miyatake, S., Okada, I., Mizuguchi, T., Doi, H.,
Saitsu, H., Miyake, N., Matsumoto, N., 2012. Mutations affecting components of
the  SWI/SNF complex cause Cofﬁn-Siris syndrome. Nat. Genet. 44, 376–378.
Valente, D., Golani, I., Mitra, P.P., 2007. Analysis of the trajectory of Drosophila
melanogaster in a circular open ﬁeld arena. PLoS One, 2.
van Alphen, B., van Swinderen, B., 2011. Drosophila strategies to study psychiatric
disorders. Brain Res. Bull. 92, 1–11.
van Bokhoven, H., 2011. Genetic and epigenetic networks in intellectual disabilities.
Ann. Rev. Genet. 45, 81–104.
van Bon, B.W.M., Oortveld, M.A.W., Nijtmans, L.G., Fenckova, M.,  Nijhof, B., Besseling,
J., Vos, M.,  Kramer, J.M., de Leeuw, N., Castells-Nobau, A., Asztalos, L., Viragh,
E.,  Ruiter, M.,  Hofmann, F., Eshuis, L., Collavin, L., Huynen, M.A., Asztalos, Z.,
Verstreken, P., Rodenburg, R.J., Smeitink, J.A., de Vries, B.B.A., Schenck, A., 2013.
CEP89 is required for mitochondrial metabolism and neuronal function in man
and ﬂy. Hum. Mol. Genet. 22, 3138–3151.
van Reeuwijk, J., Maugenre, S., van den Elzen, C., Verrips, A., Bertini, E., Muntoni, F.,
Merlini, L., Scheffer, H., Brunner, H.G., Guicheney, P., van Bokhoven, H.,  2006. The
expanding phenotype of POMT1 mutations: from Walker-Warburg syndrome
to  congenital muscular dystrophy, microcephaly, and mental retardation. Hum.
Mutat. 27, 453–459.
Veltman, J.A., Brunner, H.G., 2012. De novo mutations in human genetic disease. Nat.
Rev. Genet. 13, 565–575.
Vilella, A.J., Severin, J., Ureta-Vidal, A., Heng, L., Durbin, R., Birney, E., 2009. Ensembl
compara gene trees: complete, duplication-aware phylogenetic trees in verte-
brates. Genome Res. 19, 327–335.
Vissers, L.E., de Ligt, J., Gilissen, C., Janssen, I., Steehouwer, M.,  de Vries, P., van Lier, B.,
Arts, P., Wieskamp, N., del Rosario, M.,  van Bon, B.W., Hoischen, A., de Vries, B.B.,
Brunner, H.G., Veltman, J.A., 2010. A de novo paradigm for mental retardation.
Nat. Genet. 42, 1109–1112.
Vonhoff, F., Williams, A., Ryglewski, S., Duch, C., 2012. Drosophila as a model for
MECP2 gain of function in neurons. PLoS One 7, 21.
Wairkar, Y.P., Fradkin, L.G., Noordermeer, J.N., DiAntonio, A., 2008. Synaptic defects
in  a Drosophila model of congenital muscular dystrophy. J. Neurosci. 28,
3781–3789.
Wan, L., Dockendorff, T.C., Jongens, T.A., Dreyfuss, G., 2000. Characterization of
dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation
protein. Mol. Cell. Biol. 20, 8536–8547.
Webber, C., Hehir-Kwa, J.Y., Nguyen, D.Q., de Vries, B.B., Veltman, J.A., Ponting, C.P.,
2009. Forging links between human mental retardation-associated CNVs and
mouse gene knockout models. PLoS Genet. 5, e1000531.
Willemsen, M.H., Nijhof, B., Fenckova, M.,  Nillesen, W.M.,  Bongers, E.M.H.F., Castells-
Nobau, A., Asztalos, L., Viragh, E., van Bon, B.W.M., Tezel, E., Veltman, J.A.,
Brunner, H.G., de Vries, B.B.A., de Ligt, J., Yntema, H.G., van Bokhoven, H., Isidor,
B.,  Le Caignec, C., Lorino, E., Asztalos, Z., Koolen, D.A., Vissers, L.E.L.M., Schenck,
A.,  Kleefstra, T., 2013. GATAD2B loss-of-function mutations cause a recognisable
syndrome with intellectual disability and are associated with learning deﬁcits
and synaptic undergrowth in Drosophila. J. Med. Genet. 50, 507–514.
Willemsen, M.H., Vulto-van Silfhout, A.T., Nillesen, W.M.,  Wissink-Lindhout, W.M.,
van  Bokhoven, H., Philip, N., Berry-Kravis, E.M., Kini, U., van Ravenswaaij-Arts,
C.M., Delle Chiaie, B., Innes, A.M., Houge, G., Kosonen, T., Cremer, K., Fannemel,
M., Stray-Pedersen, A., Reardon, W.,  Ignatius, J., Lachlan, K., Mircher, C., Hel-
derman van den Enden, P.T., Mastebroek, M.,  Cohn-Hokke, P.E., Yntema, H.G.,
Drunat, S., Kleefstra, T., 2012. Update on Kleefstra syndrome. Mol. Syndromol.
2, 202–212.
Wood, A.C., Rijsdijk, F., Saudino, K.J., Asherson, P., Kuntsi, J., 2008. High heritability
for  a composite index of children’s activity level measures. Behav. Genet. 38,
266–276.
Wu,  Y., Bolduc, F.V., Bell, K., Tully, T., Fang, Y., Sehgal, A., Fischer, J.A., 2008. A
Drosophila model for Angelman syndrome. Proc. Natl. Acad. Sci. U. S. A. 105,
12399–12404.
Yan, Q.J., Rammal, M., Tranfaglia, M.,  Bauchwitz, R.P., 2005. Suppression of two major
fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP.
Neuropharmacology 49, 1053–1066.
Zafeiriou, D.I., Ververi, A., Vargiami, E., 2007. Childhood autism and associated
comorbidities. Brain Develop. 29, 257–272.
Zaghloul, N.A., Katsanis, N., 2010. Functional modules, mutational load and human
genetic disease. Trends Genet. 26, 168–176.
Zarnescu, D.C., Jin, P., Betschinger, J., Nakamoto, M.,  Wang, Y., Dockendorff, T.C., Feng,
Y.,  Jongens, T.A., Sisson, J.C., Knoblich, J.A., Warren, S.T., Moses, K., 2005. Fragile
X  protein functions with lgl and the par complex in ﬂies and mice. Devlop. Cell
8,  43–52.
Zhan, Y., Melian, N.Y., Pantoja, M.,  Haines, N., Ruohola-Baker, H., Bourque, C.W., Rao,
Y.,  Carbonetto, S., 2010. Dystroglycan and mitochondrial ribosomal protein L34
regulate differentiation in the Drosophila eye. PLoS One 5, e10488.
Zhang, J., Fang, Z., Jud, C., Vansteensel, M.J., Kaasik, K., Lee, C.C., Albrecht, U., Tamanini,
F.,  Meijer, J.H., Oostra, B.A., Nelson, D.L., 2008. Fragile X-related proteins regulate
mammalian circadian behavioral rhythms. Am. J. Hum. Genet. 83, 43–52.
Zhang, Y.Q., Bailey, A.M., Matthiens, H.J.G., Renden, R.B., Smith, M.A., Speese, S.D.,
Rubin, G.M., Broadie, K., 2001. Drosophila Fragile X-related gene regulates
MAP1B homolog Futsch to control synaptic structure and function. Cell 107,
591–603.
Zweier, C., de Jong, E.K., Zweier, M.,  Orrico, A., Ousager, L.B., Collins, A.L., Bijlsma,
E.K., Oortveld, M.A., Ekici, A.B., Reis, A., Schenck, A., Rauch, A., 2009. CNTNAP2
and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like mental retar-
dation and determine the level of a common synaptic protein in Drosophila. Am.
J.  Hum. Genet. 85, 655–666.
Zweier, C., Peippo, M.M.,  Hoyer, J., Sousa, S., Bottani, A., Clayton-Smith, J., Reardon,
W.,  Saraiva, J., Cabral, A., Gohring, I., Devriendt, K., de Ravel, T., Bijlsma, E.K.,
Hennekam, R.C., Orrico, A., Cohen, M.,  Dreweke, A., Reis, A., Nurnberg, P., Rauch,
A.,  2007. Haploinsufﬁciency of TCF4 causes syndromal mental retardation with
intermittent hyperventilation (Pitt-Hopkins syndrome). Am.  J. Hum. Genet. 80,
994–1001.
